1
|
Franchini M, Maggi F, Focosi D. ABO blood group-related mechanism of infection of SARS-CoV-2: an overview of systematic reviews. Clin Chem Lab Med 2024; 62:396-401. [PMID: 37727133 DOI: 10.1515/cclm-2023-0825] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2023] [Accepted: 08/23/2023] [Indexed: 09/21/2023]
Abstract
Among the host genetic factors playing a role in the susceptibility to infectious diseases, the ABO blood group system is of utmost importance. Following the first reports in early 2020, the association between ABO blood groups and SARS-CoV-2 infection or COVID-19 severity has been thoroughly investigated. The aim of this narrative review is to provide an overview of systematic reviews regarding the link between ABO blood groups and such risks. The possible molecular mechanisms underlying these associations will also be discussed. ABO blood group has a robust association with susceptibility to infection but not with disease severity, and studies on long COVID anre still missing.Prov.
Collapse
Affiliation(s)
- Massimo Franchini
- Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantua, Italy
| | - Fabrizio Maggi
- Laboratory of Virology, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy
| | - Daniele Focosi
- North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy
| |
Collapse
|
2
|
Al Bshabshe A, Alqahtani M, Amer KA, Al-Jahash NA, Thwab AS, Alshahrani FS, Saad Aldarani Alshahrani A, Asiri OA, Abughazalah FN, Khuzayyim AAA, Altumaihi F, Khawaji T, Algaide A, Almontasheri M. The Relationship of ABO and Rh Blood Group Types With Severe COVID-19 Disease Mortality in ICU Patients: Insights From a Single-Center Experience in Southern Saudi Arabia. Cureus 2023; 15:e50935. [PMID: 38249239 PMCID: PMC10800029 DOI: 10.7759/cureus.50935] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/21/2023] [Indexed: 01/23/2024] Open
Abstract
Introduction The global COVID-19 pandemic has triggered an unprecedented public health crisis, emphasizing the need to understand factors influencing disease outcomes. This study explores the role of genetic variations in blood group antigens, particularly ABO and RhD, in shaping mortality rates among critically ill COVID-19 patients in the southern region of Saudi Arabia. Methods Utilizing a retrospective, noninterventional approach, we analyzed medical records of 594 COVID-19 patients admitted to the intensive care unit (ICU) at Aseer Central Hospital from August 2020 to April 2021. The cohort, with a mean age of 60.5 years, consisted of a predominantly male population. Results The study encompassed a diverse age range of 18 to 103 years, with a mean age of 60.5 ± 17.3 years. Of the 594 patients, 398 (67%) were male, and only 5 (0.8%) had a history of smoking. Blood group distribution revealed 275 (48.4%) with O-, 189 (33.3%) with A+, and 51 (9%) with AB- types. Predominant chronic conditions included diabetes mellitus (35.5%). Tragically, 320 patients (54.6%) experienced mortality, with a 100% mortality rate for the B+ blood group and 92.9% for O- blood group. Conclusion This analysis establishes significant statistical links, underscoring the pivotal role of blood type, particularly the Rh factor, in influencing mortality risk among critically ill COVID-19 patients. These findings contribute valuable insights into risk stratification and personalized care for severe cases, emphasizing the importance of genetic considerations in understanding disease outcomes.
Collapse
Affiliation(s)
| | - Mushary Alqahtani
- Internal Medicine, Armed Forces Hospitals Southern Region, Khamis Mushait, SAU
| | - Khaled A Amer
- Medicine and Surgery, King Khalid University, Abha, SAU
| | | | | | | | | | | | | | | | | | - Turki Khawaji
- Intensive Care Unit, King Fahad General Hospital, Jeddah, SAU
| | - Ayman Algaide
- Intensive Care Unit, King Fahad General Hospital, Jeddah, SAU
| | - Moyed Almontasheri
- Internal Medicine, Armed Forces Hospitals Southern Region, Khamis Mushait, SAU
| |
Collapse
|
3
|
Yesilyurt S, Erinc O, Senat A, Gezmis CT, Balci MBC. Rhesus factor is a stronger predictor for the risk of Sars-CoV-2 and mortality than ABO blood types. TURKISH JOURNAL OF BIOCHEMISTRY 2023; 48:459-466. [DOI: 10.1515/tjb-2023-0063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 08/06/2024]
Abstract
Abstract
Objectives
In this study, we aimed to evaluate the relationship between ABO blood groups and Rhesus factor (Rf) and severe acute respiratory syndrome coronavirus-2 (Sars-CoV-2), as well as the risk of infection susceptibility and death according to pre-existing comorbidities.
Methods
This retrospective study included patients medical record between March 2020 and March 2021. A total 470 patients were included in the study. The subjects were categorized according to diagnose of Sars-CoV-2. Also, we evaluated the subject according to severity of Sars-CoV-2 infection. The logistic and multivariate regression analysis were performed to predict possible effect of ABO and Rf types as well as comorbidities on indicators of Sars-CoV-2 severity including Intensive care unit (ICU) hospitalization, intubation, and mortality.
Results
The distribution of ABO blood type and Rf were not statistically different cases with and without Sars-CoV-2. Blood type B and A were the most groups in intubation and mortality among patients with Sars-CoV-2. However, ABO blood types had no significant effect on risk of Sars-CoV-2 and mortality while, Rf had a significantly effect on it. Additionally, Rf had a statistically significant effect on all severity indicators of Sars-CoV-2 but ABO had not.
Conclusions
While Rf was significantly associated with risk of Sars-CoV-2 and had a strong effect on ICU admission, intubation, and mortality, ABO groups were not associated with risk of disease. Intubation and mortality rates were higher in patients with blood group B (OR: 2.93 p:0.390 95 % CI [0.253–33.9], OR: 0.217 p:0.211 95 % CI [0.020–2.37]) and Rh factor + (OR: 1.63 p:0.027 95 % CI [0.046–0.828]).
Collapse
Affiliation(s)
- Soner Yesilyurt
- Department of Internal Medicine , Taksim Training and Research Hospital , Istanbul , Türkiye
| | - Osman Erinc
- Department of Internal Medicine , Taksim Training and Research Hospital , Istanbul , Türkiye
| | - Almila Senat
- Department of Medical Biochemistry , Taksim Training and Research Hospital , Istanbul , Türkiye
| | - Cem Tugrul Gezmis
- Department of Urology , Taksim Training and Research Hospital , Istanbul , Türkiye
| | | |
Collapse
|
4
|
Berumen-Lechuga MG, Leaños-Miranda A, Molina-Pérez CJ, García-Cortes LR, Palomo-Piñón S. Risk Factors for Severe-Critical COVID-19 in Pregnant Women. J Clin Med 2023; 12:5812. [PMID: 37762753 PMCID: PMC10531823 DOI: 10.3390/jcm12185812] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2023] [Revised: 08/29/2023] [Accepted: 09/03/2023] [Indexed: 09/29/2023] Open
Abstract
Risk factors associated with severe-critical COVID-19 (coronavirus disease 2019) are based on findings in the general population. Pregnant women are at increased risk of severe-critical infection, and few reports are based on these women. A multicentric case-control study was conducted at the Mexican Institute of Social Security, State of Mexico, during the COVID-19 pandemic. We included pregnant women who were consecutively admitted to respiratory care units and were followed until 30 days after the resolution of pregnancy. A total of 758 pregnant women with a positive RT-PCR test for SARS-CoV-2 were enrolled from June 2020 to July 2021. We defined groups using the World Health Organization Severity Classification; cases were pregnant women with severe-critical COVID-19 (n = 123), and controls were subjects with non-severe COVID-19 (n = 635). Data was gathered from clinical files. A multivariate logistic regression analysis was used to adjust odds ratios and their 95% confidence intervals of factors associated with severe-critical COVID-19. Risk factors associated with severe-critical COVID-19 in pregnancy were non-vaccination (OR 10.18), blood type other than O (OR 6.29), maternal age > 35 years (OR 5.76), history of chronic hypertension (OR 5.12), gestational age at infection ≥ 31 weeks (OR 3.28), and multiparity (OR 2.80).
Collapse
Affiliation(s)
- María Guadalupe Berumen-Lechuga
- Medical Research Coordinator, Instituto Mexicano del Seguro Social, Órgano de Operación Administrativa Desconcentrada Regional Poniente, Josefa Ortiz de Domínguez S/N Colonia Centro, Toluca CP 50000, Mexico
| | - Alfredo Leaños-Miranda
- Medical Research Unit in Reproductive Medicine, Instituto Mexicano del Seguro Social, Unidad Médica de Alta Especialidad, Hospital de Ginecología y Obstetricia “Luis Castelazo Ayala”, Rio de la Magdalena 289, Tizapán San Ángel, Delegación Álvaro Obregón, Ciudad de México CP 01090, Mexico;
| | - Carlos José Molina-Pérez
- Clinical Coordinator, Instituto Mexicano del Seguro Social, Hospital General de Zona No. 252, Camino Flor de María y Calzada Señor del Huerto 154, Colonia San Martín, Atlacomulco CP 54050, Mexico;
| | - Luis Rey García-Cortes
- Medical Research Coordinator, Instituto Mexicano del Seguro Social, Órgano de Operación Administrativa Desconcentrada Regional Oriente, Calle 4 No. 25, Fraccionamiento Alce Blanco, Naucalpan CP 53370, Mexico;
| | - Silvia Palomo-Piñón
- Medical Research Unit on Nephrological Diseases (External Collaborator), Instituto Mexicano del Seguro Social, UMAE Centro Médico Nacional Siglo XXI, Avenida Cuauhtémoc 330, Colonia Doctores, Ciudad de México CP 06720, Mexico;
| |
Collapse
|
5
|
Khamees HH, Fahad MA. Impact of ABO Blood Group, Hematological, and Biochemical Abnormalities on Incidence of Patients Infected with COVID-19. ARCHIVES OF RAZI INSTITUTE 2023; 78:1193-1201. [PMID: 38226380 PMCID: PMC10787934 DOI: 10.32592/ari.2023.78.4.1193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/13/2023] [Accepted: 05/01/2023] [Indexed: 01/17/2024]
Abstract
This study aimed to investigate the relationship between blood types and COVID-19 susceptibility and explore changes in blood variables, as well as their relationship with the occurrence of COVID-19. SARS-CoV-2 is a pandemic that has affected people's health and the global financial system. Since the initial confirmed case of COVID-19, people have been influenced worldwide with varying manifestations. Moreover, researchers have illustrated a link between ABO blood types and COVID-19 susceptibility and incidence. Research has also shown that ABO blood groups might play a role in estimating COVID-19 susceptibility and death. Our analysis revealed that blood type O might probably reduce vulnerability to the SARS-CoV-2 illness. On the contrary, people with blood type A are at a higher risk of SARS-CoV-2 infection. This study also evaluated liver biomarkers among COVID-19 patients, revealing significant abnormalities in the levels of alanine amino transferees, aspartate amino transferees, gamma-glutamyl transferees, and total bilirubin.
Collapse
Affiliation(s)
- H H Khamees
- Medical Laboratory Techniques Department, Dijlah University College, Baghdad, Iraq
| | - M A Fahad
- Forensic Evidences Department, Al Salam university College, Baghdad, Iraq
| |
Collapse
|
6
|
Abdulla SA, Elawamy HA, Mohamed NAE, Abduallah EH, Amshahar HAA, Abuzaeid NK, Eisa MAM, Osman MEM, Konozy EHE. Association of ABO blood types and clinical variables with COVID-19 infection severity in Libya. SAGE Open Med 2023; 11:20503121231187736. [PMID: 37489137 PMCID: PMC10363681 DOI: 10.1177/20503121231187736] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Accepted: 06/25/2023] [Indexed: 07/26/2023] Open
Abstract
Objective The continuing COVID-19 pandemic is a coronavirus-related health emergency (severe acute respiratory syndrome coronavirus 2). Inadequate efforts are still being made to address the illness situation in Libya, and this must change. To address these issues, we looked into the demography and trend of the disease as well as the potential risk factors for infection. Methods This study is a retrospective case-control study conducted online among 616 COVID-19 patients. The p0.05 value, odds ratios, and 95% confidence intervals were calculated and analyzed from the drawn data. Results Males were at high risk of COVID-19 than females (odds ratio = 1.3, 95% confidence interval: 1.042-1.622; p = 0.02). Anosmia and ageusia were more prominent in females. Patients with an "AB" blood group are significantly susceptible to infection. Adults (31 and above) are highly liable to infection. The univariate logistic regression analysis revealed that smoking is a risk factor for those above 60 years (odds ratio = 2.228, 95% confidence interval: 1.145-4.336; p = 0.018). Individuals with chronic diseases such as diabetes and/or hypertension are more prone to COVID-19 (odds ratio = 10.045, 95% confidence interval: 3.078-32.794; p = 0.000 and odds ratio = 11.508, 95% confidence interval: 3.930-33.695; p = 0.000, respectively). Conclusion This study provided for the first time the demographic data and the trend of COVID-19 infection in Libya, which will assist the stakeholders and governmental bodies in planning protection strategies against the pandemic.
Collapse
Affiliation(s)
- Sara A Abdulla
- Department of Biochemistry, Faculty of Medicine, University of Benghazi, Benghazi, Libya
| | | | - Negia AE Mohamed
- Department of Biochemistry, Faculty of Medicine, University of Benghazi, Benghazi, Libya
| | - Enas H Abduallah
- Department of Mathematics, Faculty of Science, University of Tobruk, Tobruk, Libya
| | - Habsa AA Amshahar
- Department of Pathology, Faculty of Medicine, Sirte University, Sirte, Libya
| | - Nadir K Abuzaeid
- Department of Medical Microbiology, Faculty of Medical Laboratory of Sciences, Omdurman Islamic University, Khartoum, Sudan
| | - Mohamed AM Eisa
- Department of Physiology, Al Qunfudah Medical College, Umm Al Qura University, Al Qunfudah, Saudi Arabia
| | - Makarim Elfadil M Osman
- Laboratory of Proteomics and Glycoproteins, Biotechnology Park, Africa City of Technology, Khartoum, Sudan
| | - Emadeldin Hassan E Konozy
- Laboratory of Proteomics and Glycoproteins, Biotechnology Park, Africa City of Technology, Khartoum, Sudan
- Pharmaceutical Research and Development Centre, Faculty of Pharmacy, Karary University, Omdurman, Khartoum State, Sudan
| |
Collapse
|
7
|
Zeng X, Fan H, Kou J, Lu D, Huang F, Meng X, Liu H, Li Z, Tang M, Zhang J, Liu N, Hu X. Analysis between ABO blood group and clinical outcomes in COVID-19 patients and the potential mediating role of ACE2. Front Med (Lausanne) 2023; 10:1167452. [PMID: 37425304 PMCID: PMC10327892 DOI: 10.3389/fmed.2023.1167452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2023] [Accepted: 06/07/2023] [Indexed: 07/11/2023] Open
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become the most common coronavirus that causes large-scale infections worldwide. Currently, several studies have shown that the ABO blood group is associated with coronavirus disease 2019 (COVID-19) infection and some studies have also suggested that the infection of COVID-19 may be closely related to the interaction between angiotensin-converting enzyme 2 (ACE2) and blood group antigens. However, the relationship between blood type to clinical outcome in critically ill patients and the mechanism of action is still unclear. The current study aimed to examine the correlation between blood type distribution and SARS-CoV-2 infection, progression, and prognosis in patients with COVID-19 and the potential mediating role of ACE2. With 234 patients from 5 medical centers and two established cohorts, 137 for the mild cohort and 97 for the critically ill cohort, we found that the blood type A population was more sensitive to SARS-CoV-2, while the blood type distribution was not relevant to acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), and mortality in COVID-19 patients. Further study showed that the serum ACE2 protein level of healthy people with type A was significantly higher than that of other blood groups, and type O was the lowest. The experimental results of spike protein binding to red blood cells also showed that the binding rate of people with type A was the highest, and that of people with type O was the lowest. Our finding indicated that blood type A may be the biological marker for susceptibility to SARS-CoV-2 infection and may be associated with potential mediating of ACE2, but irrelevant to the clinical outcomes including ARDS, AKI, and death. These findings can provide new ideas for clinical diagnosis, treatment, and prevention of COVID-19.
Collapse
Affiliation(s)
- Xianfei Zeng
- School of Medicine, Northwest University, Xi'an, China
- Xi'an Area Medical Laboratory Center, Xi’an, China
| | - Hongyan Fan
- Department of Blood Transfusion, 940 Hospital, Lanzhou, China
| | - Jinxin Kou
- School of Medicine, Northwest University, Xi'an, China
| | - Dongxue Lu
- Department of Anesthesiology and Perioperative Medicine, Xijing Hospital, Xi’an, China
| | - Fang Huang
- Department of Laboratory Medicine, Xi’an Chest Hospital, Xi’an, China
| | - Xi Meng
- Xi'an Area Medical Laboratory Center, Xi’an, China
| | - Haiying Liu
- Xi'an Area Medical Laboratory Center, Xi’an, China
| | - Zhuo Li
- Department of Laboratory Medicine, First Affiliated Hospital of Xi'an Medical University, Xi’an, China
| | - Mei Tang
- Department of Blood Transfusion, Tangdu Hospital, Xi’an, China
| | - Jing Zhang
- Department of Blood Transfusion, Xijing Hospital, Xi’an, China
| | - Nannan Liu
- Intensive Care Center, Xijing Hospital, Xi’an, China
| | - Xingbin Hu
- Department of Blood Transfusion, Xijing Hospital, Xi’an, China
| |
Collapse
|
8
|
Sevilla-Montoya R, Helguera-Reppeto AC, Monroy-Muñoz IE, Vargas-Pavia TA, Valdés-Montoya EI, Solis-Paredes M, Torres-Torres J, Velazquez-Cruz R, Muñoz-Medina JE, Martinez-Cordero C, Hidalgo-Bravo A. Blood Type Associated with the Risk of COVID-19 Infection in Pregnant Women. Diagnostics (Basel) 2023; 13:diagnostics13071338. [PMID: 37046556 PMCID: PMC10093519 DOI: 10.3390/diagnostics13071338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2023] [Revised: 03/09/2023] [Accepted: 03/14/2023] [Indexed: 04/07/2023] Open
Abstract
COVID-19 forced us to investigate risk factors to provide the best medical attention, especially in vulnerable groups, such as pregnant patients. Studies in other populations have analyzed blood groups in relation to infection, complications, and death. The present study aimed to analyze the association of blood groups with the risk of infection and complications in pregnant women and newborns from the Mexican-Mestizo population. We studied 1906 individuals. Quantitative variables were analyzed through the Student’s t-test. Categorical variables were analyzed through Pearson’s chi-square test, and logistic regression was used to analyze the association between categorical variables and outcomes. No significant association was observed between blood groups and infection risk. Individuals with the AB blood type are at higher risk for developing severe disease, although blood groups do not seem to be involved in the risk of SARS-CoV-2 infection. However, the AB blood group could be considered a risk factor for developing severe COVID-19 in the Mexican population.
Collapse
Affiliation(s)
- Rosalba Sevilla-Montoya
- Reproductive Research and Perinatal Health Department, National Institute of Perinatology, Mexico City 11000, Mexico
| | | | - Irma E. Monroy-Muñoz
- Reproductive Research and Perinatal Health Department, National Institute of Perinatology, Mexico City 11000, Mexico
| | - Tania A. Vargas-Pavia
- Immunobiochemistry Department, National Institute of Perinatology, Mexico City 11000, Mexico
| | - Elías I. Valdés-Montoya
- Immunobiochemistry Department, National Institute of Perinatology, Mexico City 11000, Mexico
| | - Mario Solis-Paredes
- Reproductive Research and Perinatal Health Department, National Institute of Perinatology, Mexico City 11000, Mexico
| | - Johnatan Torres-Torres
- Reproductive Research and Perinatal Health Department, National Institute of Perinatology, Mexico City 11000, Mexico
| | - Rafael Velazquez-Cruz
- Laboratory of Bone Metabolism, National Institute of Genomic Medicine (INMEGEN), Mexico City 14610, Mexico
| | - José Esteban Muñoz-Medina
- Surveillance and Epidemiological Research Laboratories Division, Mexican Institute of Social Security, Mexico City 06700, Mexico
| | | | - Alberto Hidalgo-Bravo
- Genomics Medicine Department, National Institute of Rehabilitation, Mexico City 14389, Mexico
| |
Collapse
|
9
|
Domènech-Montoliu S, Puig-Barberà J, Guerra-Murcia O, Pac-Sa MR, Orrico-Sanchéz A, Gómez-Lanas L, Sala-Trull D, Domènech-Leon C, Del Rio-González A, Sánchez-Urbano M, Satorres-Martinez P, Latorre-Poveda M, Ferrando-Rubert S, Aparisi-Esteve L, Badenes-Marques G, Blasco-Gari R, Casanova-Suarez J, Fontal-Carcel M, Gil-Fortuño M, Hernández-Pérez N, Jovani-Sales D, López-Diago L, Notari-Rodríguez C, Pérez-Olaso O, Romeu-Garcia MA, Ruíz-Puig R, Arnedo-Pena A. ABO Blood Groups and Incidence of COVID-19 in the Mass Gathering Events in Borriana (Spain), March 2020: A Retrospective Cohort Study. EPIDEMIOLOGIA 2023; 4:63-73. [PMID: 36810454 PMCID: PMC9944070 DOI: 10.3390/epidemiologia4010007] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2022] [Revised: 01/19/2023] [Accepted: 01/24/2023] [Indexed: 02/01/2023] Open
Abstract
Our objective was to estimate the incidence of COVID-19 and the ABO blood Groups in the mass-gathering events (MGEs) during the Falles Festival in Borriana (Spain) from 6-10 March 2020. We conducted a population-based retrospective cohort study and measured anti-SARS-CoV-2 antibodies and the ABO of participants. We performed laboratory COVID-19 tests and obtained the ABO in 775 subjects (72.8% of the original exposed cohort): O-group (45.2%), A-group (43.1%), B-group (8.5%) and AB-group (3.4%). Adjusted for confounding factors, including COVID-19 exposure during the MGEs, attack rates of COVID-19 for each ABO group were 55.4%, 59.6%, 60.2%, and 63.7%. The adjusted relative risks were for O-group 0.93 (95% Confidence Interval [CI] 0.83-1.04), for A-group 1.06 (95% CI 0.94-1.18), for B-group 1.04 (95%CI 0.88-1.24), and for AB-group 1.11 (95% CI 0.81-1.51) with no significant differences. Conclusions: Our results suggest no effect of ABO on COVID-19 incidence. We observed weak but not significant protection of the O-group and not a significantly greater infection risk for the remaining groups compared with the O-group. More studies are needed to resolve the controversies regarding the association between ABO and COVID-19.
Collapse
Affiliation(s)
| | - Joan Puig-Barberà
- Vaccines Research Unit, Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, FISABIO-Public Health, 46020 Valencia, Spain
| | - Olga Guerra-Murcia
- Vaccines Research Unit, Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, FISABIO-Public Health, 46020 Valencia, Spain
| | | | - Alejandro Orrico-Sanchéz
- Vaccines Research Unit, Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, FISABIO-Public Health, 46020 Valencia, Spain
- Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain
- Universidad Católica de Valencia San Vicente Mártir, 46001 Valencia, Spain
| | - Lorna Gómez-Lanas
- Emergency Service University Hospital de la Plana, 12540 Vila-real, Spain
| | - Diego Sala-Trull
- Emergency Service University Hospital de la Plana, 12540 Vila-real, Spain
| | | | | | | | | | | | | | | | | | - Roser Blasco-Gari
- Emergency Service University Hospital de la Plana, 12540 Vila-real, Spain
| | | | | | - María Gil-Fortuño
- Microbiology Service University Hospital de la Plana, 12540 Vila-real, Spain
| | | | - David Jovani-Sales
- Emergency Service University Hospital de la Plana, 12540 Vila-real, Spain
| | - Laura López-Diago
- Clinical Analysis Service University Hospital de la Plana, 12540 Vila-real, Spain
| | | | - Oscar Pérez-Olaso
- Microbiology Service University Hospital de la Plana, 12540 Vila-real, Spain
| | | | - Raquel Ruíz-Puig
- Emergency Service University Hospital de la Plana, 12540 Vila-real, Spain
| | - Alberto Arnedo-Pena
- Public Health Center, 12003 Castelló de la Plana, Spain
- Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain
- Department of Health Science, Public University Navarra, 31006 Pamplona, Spain
- Correspondence:
| |
Collapse
|
10
|
Moslemi C, Sækmose S, Larsen R, Brodersen T, Didriksen M, Hjalgrim H, Banasik K, Nielsen KR, Bruun MT, Dowsett J, Kasperen KA, Mikkelsen S, Hansen TF, Ullum H, Erikstrup C, Olsson ML, Ostrowski SR, Pedersen OB. A large cohort study of the effects of Lewis, ABO, 13 other blood groups, and secretor status on COVID-19 susceptibility, severity, and long COVID-19. Transfusion 2023; 63:47-58. [PMID: 36271437 PMCID: PMC9874484 DOI: 10.1111/trf.17170] [Citation(s) in RCA: 10] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2022] [Revised: 08/15/2022] [Accepted: 09/14/2022] [Indexed: 01/27/2023]
Abstract
BACKGROUND Previous studies have reported Blood type O to confer a lower risk of SARS-CoV-2 infection, while secretor status and other blood groups have been suspected to have a similar effect as well. STUDY DESIGN AND METHODS To determine whether any other blood groups influence testing positive for SARS-CoV-2, COVID-19 severity, or prolonged COVID-19, we used a large cohort of 650,156 Danish blood donors with varying available data for secretor status and blood groups ABO, Rh, Colton, Duffy, Diego, Dombrock, Kell, Kidd, Knops, Lewis, Lutheran, MNS, P1PK, Vel, and Yt. Of these, 36,068 tested positive for SARS-CoV-2 whereas 614,088 tested negative between 2020-02-17 and 2021-08-04. Associations between infection and blood groups were assessed using logistic regression models with sex and age as covariates. RESULTS The Lewis blood group antigen Lea displayed strongly reduced SARS-CoV-2 susceptibility OR 0.85 CI[0.79-0.93] p < .001. Compared to blood type O, the blood types B, A, and AB were found more susceptible toward infection with ORs 1.1 CI[1.06-1.14] p < .001, 1.17 CI[1.14-1.2] p < .001, and 1.2 CI[1.14-1.26] p < .001, respectively. No susceptibility associations were found for the other 13 blood groups investigated. There was no association between any blood groups and COVID-19 hospitalization or long COVID-19. No secretor status associations were found. DISCUSSION This study uncovers a new association to reduced SARS-CoV-2 susceptibility for Lewis type Lea and confirms the previous link to blood group O. The new association to Lea could be explained by a link between mucosal microbiome and SARS-CoV-2.
Collapse
Affiliation(s)
- Camous Moslemi
- Department of Clinical ImmunologyZealand University HospitalKøgeDenmark
| | - Susanne Sækmose
- Department of Clinical ImmunologyZealand University HospitalKøgeDenmark
| | - Rune Larsen
- Department of Clinical ImmunologyZealand University HospitalKøgeDenmark
| | | | - Maria Didriksen
- Department of Clinical ImmunologyCopenhagen University Hospital, RigshopitaletCopenhagenDenmark
| | - Henrik Hjalgrim
- Department of Clinical ImmunologyAarhus University HospitalSkejbyDenmark
| | - Karina Banasik
- Novo Nordisk Foundation Center for Protein ResearchUniversity of CopenhagenCopenhagenDenmark
| | - Kaspar R. Nielsen
- Department of Clinical ImmunologyAalborg University HospitalAalborgDenmark
| | - Mie T. Bruun
- Department of Clinical ImmunologyOdense University HospitalOdenseDenmark
| | - Joseph Dowsett
- Department of Clinical ImmunologyCopenhagen University Hospital, RigshopitaletCopenhagenDenmark
| | - Kathrine A. Kasperen
- Danish Cancer Society Research CenterCopenhagenDenmark,Danish Big Data Centre for Environment and Health (BERTHA)Aarhus UniversityRoskildeDenmark
| | | | - Thomas F. Hansen
- Novo Nordisk Foundation Center for Protein ResearchUniversity of CopenhagenCopenhagenDenmark,Department of NeurologyNeuroGenomic group, RigshospitaletGlostrupDenmark
| | | | | | - Martin L. Olsson
- Department of Laboratory MedicineLund UniversityLundSweden,Department of Clinical Immunology and Transfusion MedicineOffice for Medical ServicesLundSweden
| | - Sisse R. Ostrowski
- Department of Clinical ImmunologyCopenhagen University Hospital, RigshopitaletCopenhagenDenmark,Department of Clinical Medicine, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark
| | - Ole B. Pedersen
- Department of Clinical ImmunologyZealand University HospitalKøgeDenmark,Department of Clinical Medicine, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark
| |
Collapse
|
11
|
Rabaan AA, Mutair AA, Aljeldah M, Shammari BRA, Sulaiman T, Alshukairi AN, Alfaresi M, Al-Jishi JM, Al Bati NA, Al-Mozaini MA, Bshabshe AA, Almatouq JA, Abuzaid AA, Alfaraj AH, Al-Adsani W, Alabdullah M, Alwarthan S, Alsalman F, Alwashmi ASS, Alhumaid S. Genetic Variants and Protective Immunity against SARS-CoV-2. Genes (Basel) 2022; 13:genes13122355. [PMID: 36553622 PMCID: PMC9778397 DOI: 10.3390/genes13122355] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Revised: 12/09/2022] [Accepted: 12/10/2022] [Indexed: 12/16/2022] Open
Abstract
The novel coronavirus-19 (SARS-CoV-2), has infected numerous individuals worldwide, resulting in millions of fatalities. The pandemic spread with high mortality rates in multiple waves, leaving others with moderate to severe symptoms. Co-morbidity variables, including hypertension, diabetes, and immunosuppression, have exacerbated the severity of COVID-19. In addition, numerous efforts have been made to comprehend the pathogenic and host variables that contribute to COVID-19 susceptibility and pathogenesis. One of these endeavours is understanding the host genetic factors predisposing an individual to COVID-19. Genome-Wide Association Studies (GWAS) have demonstrated the host predisposition factors in different populations. These factors are involved in the appropriate immune response, their imbalance influences susceptibility or resistance to viral infection. This review investigated the host genetic components implicated at the various stages of viral pathogenesis, including viral entry, pathophysiological alterations, and immunological responses. In addition, the recent and most updated genetic variations associated with multiple host factors affecting COVID-19 pathogenesis are described in the study.
Collapse
Affiliation(s)
- Ali A. Rabaan
- Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311, Saudi Arabia
- College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia
- Department of Public Health and Nutrition, The University of Haripur, Haripur 22610, Pakistan
- Correspondence:
| | - Abbas Al Mutair
- Research Center, Almoosa Specialist Hospital, Al-Ahsa 36342, Saudi Arabia
- College of Nursing, Princess Norah Bint Abdulrahman University, Riyadh 11564, Saudi Arabia
- School of Nursing, Wollongong University, Wollongong, NSW 2522, Australia
- Nursing Department, Prince Sultan Military College of Health Sciences, Dhahran 33048, Saudi Arabia
| | - Mohammed Aljeldah
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Hafr Al Batin, Hafr Al Batin 39831, Saudi Arabia
| | - Basim R. Al Shammari
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Hafr Al Batin, Hafr Al Batin 39831, Saudi Arabia
| | - Tarek Sulaiman
- Infectious Diseases Section, Medical Specialties Department, King Fahad Medical City, Riyadh 12231, Saudi Arabia
| | - Abeer N. Alshukairi
- College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia
- Department of Medicine, King Faisal Specialist Hospital and Research Center, Jeddah 21499, Saudi Arabia
| | - Mubarak Alfaresi
- Department of Pathology and Laboratory Medicine, Sheikh Khalifa General Hospital, Umm Al Quwain 499, United Arab Emirates
- Department of Pathology, College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai 505055, United Arab Emirates
| | - Jumana M. Al-Jishi
- Internal Medicine Department, Qatif Central Hospital, Qatif 35342, Saudi Arabia
| | - Neda A. Al Bati
- Medical and Clinical Affairs, Rural Health Network, Eastern Health Cluster, Dammam 31444, Saudi Arabia
| | - Maha A. Al-Mozaini
- Immunocompromised Host Research Section, Department of Infection and Immunity, King Faisal, Specialist Hospital and Research Centre, Riyadh 11564, Saudi Arabia
| | - Ali Al Bshabshe
- Adult Critical Care Department of Medicine, Division of Adult Critical Care, College of Medicine, King Khalid University, Abha 62561, Saudi Arabia
| | - Jenan A. Almatouq
- Department of Clinical Laboratory Sciences, Mohammed Al-Mana College of Health Sciences, Dammam 34222, Saudi Arabia
| | - Abdulmonem A. Abuzaid
- Medical Microbiology Department, Security Forces Hospital Programme, Dammam 32314, Saudi Arabia
| | - Amal H. Alfaraj
- Pediatric Department, Abqaiq General Hospital, First Eastern Health Cluster, Abqaiq 33261, Saudi Arabia
| | - Wasl Al-Adsani
- Department of Medicine, Infectious Diseases Hospital, Kuwait City 63537, Kuwait
- Department of Infectious Diseases, Hampton Veterans Administration Medical Center, Hampton, VA 23667, USA
| | - Mohammed Alabdullah
- Department of Infectious Diseases, Almoosa Specialist Hospital, Al Mubarraz 36342, Saudi Arabia
| | - Sara Alwarthan
- Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam 34212, Saudi Arabia
| | - Fatimah Alsalman
- Department of Emergency Medicine, Oyun City Hospital, Al-Ahsa 36312, Saudi Arabia
| | - Ameen S. S. Alwashmi
- Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia
| | - Saad Alhumaid
- Administration of Pharmaceutical Care, Al-Ahsa Health Cluster, Ministry of Health, Al-Ahsa 31982, Saudi Arabia
| |
Collapse
|
12
|
Aloor A, Aradhya R, Venugopal P, Gopalakrishnan Nair B, Suravajhala R. Glycosylation in SARS-CoV-2 variants: A path to infection and recovery. Biochem Pharmacol 2022; 206:115335. [PMID: 36328134 PMCID: PMC9621623 DOI: 10.1016/j.bcp.2022.115335] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2022] [Revised: 10/25/2022] [Accepted: 10/25/2022] [Indexed: 11/05/2022]
Abstract
Glycan is an essential molecule that controls and drives life in a precise direction. The paucity of research in glycobiology may impede the significance of its role in the pandemic guidelines. The SARS-CoV-2 spike protein is heavily glycosylated, with 22 putative N-glycosylation sites and 17 potential O-glycosylation sites discovered thus far. It is the anchor point to the host cell ACE2 receptor, TMPRSS2, and many other host proteins that can be recognized by their immune system; hence, glycosylation is considered the primary target of vaccine development. Therefore, it is essential to know how this surface glycan plays a role in viral entry, infection, transmission, antigen, antibody responses, and disease progression. Although the vaccines are developed and applied against COVID-19, the proficiency of the immunizations is not accomplished with the current mutant variations. The role of glycosylation in SARS-CoV-2 and its receptor ACE2 with respect to other putative cell glycan receptors and the significance of glycan in host cell immunity in COVID-19 are discussed in this paper. Hence, the molecular signature of the glycan in the coronavirus infection can be incorporated into the mainstream therapeutic process.
Collapse
Affiliation(s)
- Arya Aloor
- School of Biotechnology, Amrita Vishwa Vidyapeetham, Amritapuri, Clappana 690525, Kerala, India.
| | - Rajaguru Aradhya
- School of Biotechnology, Amrita Vishwa Vidyapeetham, Amritapuri, Clappana 690525, Kerala, India.
| | - Parvathy Venugopal
- School of Biotechnology, Amrita Vishwa Vidyapeetham, Amritapuri, Clappana 690525, Kerala, India.
| | | | - Renuka Suravajhala
- School of Biotechnology, Amrita Vishwa Vidyapeetham, Amritapuri, Clappana 690525, Kerala, India.
| |
Collapse
|
13
|
ABO rs657152 and Blood Groups Are as Predictor Factors of COVID-19 Mortality in the Iranian Population. DISEASE MARKERS 2022; 2022:5988976. [PMID: 36419842 PMCID: PMC9678483 DOI: 10.1155/2022/5988976] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/01/2022] [Revised: 10/07/2022] [Accepted: 11/07/2022] [Indexed: 11/16/2022]
Abstract
Several studies have discovered a relationship between specific blood types, genetic variations of the ABO gene, and coronavirus disease 2019 (COVID-19). Therefore, the aim of this study was to evaluate the association between ABO rs657152 polymorphisms and ABO blood groups with COVID-19 mortality. The tetraprimer amplification refractory mutation system, polymerase chain reaction method, was used for ABO rs657152 polymorphism genotyping in 1,211 dead and 1,442 improved patients. In the current study, the frequency of ABO rs657152 AA than CC genotypes was significantly higher in dead patients than in improved patients. Our findings indicated that blood type A was associated with the highest risk of COVID-19 mortality compared to other blood groups, and patients with blood type O have a lower risk of infection, suggesting that blood type O may be a protective factor against COVID-19 mortality. Multivariate logistic regression test indicated that higher COVID-19 mortality rates were linked with alkaline phosphatase, alanine aminotransferase, high density lipoprotein, low-density lipoprotein, fasting blood glucose, uric acid, creatinine, erythrocyte sedimentation rate, C-reactive protein, 25-hydroxyvitamin D, real-time PCR Ct values, ABO blood groups, and ABO rs657152 AA genotype. In conclusion, the AA genotype of ABO rs657152 and blood type A were associated with a considerably increased frequency of COVID-19 mortality. Further research is necessary to validate the obtained results.
Collapse
|
14
|
Bullerdiek J, Reisinger E, Rommel B, Dotzauer A. ABO blood groups and the risk of SARS-CoV-2 infection. PROTOPLASMA 2022; 259:1381-1395. [PMID: 35364749 PMCID: PMC8973646 DOI: 10.1007/s00709-022-01754-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/18/2021] [Accepted: 03/08/2022] [Indexed: 05/08/2023]
Abstract
There is no doubt that genetic factors of the host play a role in susceptibility to infectious diseases. An association between ABO blood groups and SARS-CoV-2 infection as well as the severity of COVID-19 has been suggested relatively early during the pandemic and gained enormously high public interest. It was postulated that blood group A predisposes to a higher risk of infection as well as to a much higher risk of severe respiratory disease and that people with blood group O are less frequently and less severely affected by the disease. However, as to the severity of COVID-19, a thorough summary of the existing literature does not support these assumptions in general. Accordingly, at this time, there is no reason to suppose that knowledge of a patient's ABO phenotype should directly influence therapeutical decisions in any way. On the other hand, there are many data available supporting an association between the ABO blood groups and the risk of contracting SARS-CoV-2. To explain this association, several interactions between the virus and the host cell membrane have been proposed which will be discussed here.
Collapse
Affiliation(s)
- Jörn Bullerdiek
- Institute for Medical Genetics, University of Rostock, University Medicine, Ernst-Heydemann-Strasse 8, 18057, Rostock, Germany.
- Human Genetics, University of Bremen, Leobener Strasse 2, 28359, Bremen, Germany.
| | - Emil Reisinger
- Department of Tropical Medicine and Infectious Diseases, Ernst-Heydemann-Strasse 6, 18055, Rostock, Germany
| | - Birgit Rommel
- Human Genetics, University of Bremen, Leobener Strasse 2, 28359, Bremen, Germany
| | - Andreas Dotzauer
- Laboratory of Virus Research, University of Bremen, Leobener Strasse 6, 28359, Bremen, Germany
| |
Collapse
|
15
|
Bshaena AM, Almajdoub OH, Alshwesh RA, Omran EA, Haq S, Ismail F. Association Between ABO Blood Group System and COVID-19 Severity. Am J Clin Pathol 2022; 158:570-573. [PMID: 36069364 PMCID: PMC9494408 DOI: 10.1093/ajcp/aqac106] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2022] [Accepted: 07/26/2022] [Indexed: 01/09/2023] Open
Abstract
OBJECTIVES A possible association between blood group systems (ABO and Rh) and coronavirus disease 2019 (COVID-19) severity has recently been investigated by various studies with conflicting results. However, due to variations in the prevalence of the ABO and Rh blood groups in different populations, their association with COVID-19 might be varied as well. Therefore, we conducted this study on Libyan participants to further investigate this association and make population-based data available to the worldwide scientific community. METHODS In this case-control study, ABO and Rh blood groups in 419 confirmed COVID-19 cases in Zawia, Libya, and 271 healthy controls were compared using descriptive statistics and χ 2 tests. RESULTS Blood group A was significantly more prevalent in patients with severe COVID-19 (64/125; 51.2%) than in patients with nonsevere COVID-19 (108/294, 36.7%) (P < .034), whereas the O blood group prevalence was higher in nonsevere COVID-19 cases (131/294, 44.5%) compared with severe cases (43/125, 34.4%) (P < .001). CONCLUSIONS The results showed a significant association between blood group A and the severity of COVID-19, whereas patients with blood group O showed a low risk of developing severe COVID-19 infection. No significant association was found between Rh and susceptibility/severity of the disease.
Collapse
Affiliation(s)
- Amina M Bshaena
- Department of Research and Consultation, Libyan Medical Research Centre, Zawia, Libya
| | - Osama H Almajdoub
- Department of Chemistry, Libyan Medical Research Centre, Zawia, Libya
| | - Rajaa A Alshwesh
- Department of Physiology, Faculty of Medicine, Zawia University, Zawia, Libya
| | - Entesar A Omran
- Department of Pharmacology, Faculty of Medicine, Zawia University, Zawia, Libya
| | - Soghra Haq
- Department of Clinical Laboratory, Faculty of Medical Technology, Tobruk University, Tobruk, Libya
| | | |
Collapse
|
16
|
Luo J, Craver A, Zakin P, Stepniak L, Moore K, King J, Kibriya MG, Johnson J, Olopade CO, Pinto JM, Kim K, Ahsan H, Aschebrook‐Kilfoy B. Race may modify the association between blood type and COVID-19 infection. EJHAEM 2022; 3:903-907. [PMID: 35945975 PMCID: PMC9353380 DOI: 10.1002/jha2.539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 06/21/2022] [Revised: 07/13/2022] [Accepted: 07/17/2022] [Indexed: 06/15/2023]
Abstract
This study aims to investigate the race/ethnicity-specific association between blood type and COVID-19 susceptibility during March, 2020 and December, 2021 using data from the electronic health record at the University of Chicago Medicine. The study population was stratified into four groups: non-Hispanic White, non-Hispanic Black, Hispanic, and other. Log-binomial generalized mixed model was used to estimate the relative risk (RR) and 95% confidence interval (CI). When compared to blood type O, type B was associated with positive COVID-19 test in Blacks (RR = 1.12, 95% CI: 1.02-1.23), Whites (RR = 1.28, 95% CI: 0.99-1.66), and Hispanic (RR = 1.36, 95% CI: 0.97-1.92).
Collapse
Affiliation(s)
- Jiajun Luo
- Department of Public Health SciencesUniversity of ChicagoChicagoIllinois
- Institute for Population and Precision HealthUniversity of ChicagoChicagoIllinois
- Comprehensive Cancer CenterUniversity of ChicagoChicagoIllinois
| | - Andrew Craver
- Institute for Population and Precision HealthUniversity of ChicagoChicagoIllinois
| | - Paul Zakin
- Department of Public Health SciencesUniversity of ChicagoChicagoIllinois
- Institute for Population and Precision HealthUniversity of ChicagoChicagoIllinois
| | - Liz Stepniak
- Department of Public Health SciencesUniversity of ChicagoChicagoIllinois
- Institute for Population and Precision HealthUniversity of ChicagoChicagoIllinois
- Comprehensive Cancer CenterUniversity of ChicagoChicagoIllinois
| | - Kayla Moore
- Department of Public Health SciencesUniversity of ChicagoChicagoIllinois
- Institute for Population and Precision HealthUniversity of ChicagoChicagoIllinois
| | - Jaime King
- Department of Public Health SciencesUniversity of ChicagoChicagoIllinois
- Institute for Population and Precision HealthUniversity of ChicagoChicagoIllinois
| | - Muhammad G. Kibriya
- Department of Public Health SciencesUniversity of ChicagoChicagoIllinois
- Institute for Population and Precision HealthUniversity of ChicagoChicagoIllinois
| | - Julie Johnson
- Center for Research InformaticsUniversity of ChicagoChicagoIllinois
| | | | | | - Karen Kim
- Institute for Population and Precision HealthUniversity of ChicagoChicagoIllinois
- Comprehensive Cancer CenterUniversity of ChicagoChicagoIllinois
- Department of MedicineUniversity of ChicagoChicagoIllinois
| | - Habibul Ahsan
- Department of Public Health SciencesUniversity of ChicagoChicagoIllinois
- Institute for Population and Precision HealthUniversity of ChicagoChicagoIllinois
- Comprehensive Cancer CenterUniversity of ChicagoChicagoIllinois
| | - Briseis Aschebrook‐Kilfoy
- Department of Public Health SciencesUniversity of ChicagoChicagoIllinois
- Institute for Population and Precision HealthUniversity of ChicagoChicagoIllinois
- Comprehensive Cancer CenterUniversity of ChicagoChicagoIllinois
| |
Collapse
|
17
|
Hafez W, Ahmed S, Abbas N, Ahmed K, Kamran S, Arya A, Rao SR, Abdelshakor M, Ali S, Sebastian H, Tariq M, Lal K, Abdelrahman A. ABO Blood Group in Relation to COVID-19 Susceptibility and Clinical Outcomes: A Retrospective Observational Study in the United Arab Emirates. LIFE (BASEL, SWITZERLAND) 2022; 12:life12081157. [PMID: 36013335 PMCID: PMC9410437 DOI: 10.3390/life12081157] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/13/2022] [Revised: 07/18/2022] [Accepted: 07/25/2022] [Indexed: 11/21/2022]
Abstract
(1) Background: The association between ABO blood groups and COVID-19 outcomes was investigated in several studies. The results were controversial. This study aimed to explore the association between ABO blood groups and COVID-19 outcomes. (2) Methods: This retrospective study included 303 COVID-19 patients treated at the NMC Royal Hospital in the United Arab Emirates between 8 April 2020 and 30 June 2020. (3) Results: The mean age of patients included in the study was 39.3 ± 10.7 years, and 72.9% of patients were males. The prevalence of blood groups O, A, B, and AB was 40.3%, 27.7%, 25.1%, and 6.9%, respectively. The correlation between ABO blood groups and COVID-19 outcomes was insignificant except in the AB group, with significantly higher odds of disease severity. Increased age, higher body mass index (BMI), and being of male gender increased the risk for pneumonia among all blood groups. Both increased age and higher BMI increased the risk of mortality, and increased age increased the risk of disease severity. Troponin and platelet counts were significantly different in the A group compared to the non-A groups. Time to viral clearance was not different among blood groups. However, adjustment for Rh groups resulted in a significantly shorter time in the B group. (4) Conclusions: There was no significant association between ABO blood groups and COVID-19 outcomes, with the exception of group AB.
Collapse
Affiliation(s)
- Wael Hafez
- NMC Royal Hospital, Abu Dhabi P.O. Box 35233, United Arab Emirates; (S.A.); (N.A.); (K.A.); (S.K.); (A.A.); (S.R.R.); (M.A.); (S.A.); (H.S.); (M.T.); (K.L.); (A.A.)
- The Medical Research Division, Department of Internal Medicine, The National Research Center, Cairo 12622, Egypt
- Correspondence: ; Tel.: +971-2203-5000
| | - Shougyat Ahmed
- NMC Royal Hospital, Abu Dhabi P.O. Box 35233, United Arab Emirates; (S.A.); (N.A.); (K.A.); (S.K.); (A.A.); (S.R.R.); (M.A.); (S.A.); (H.S.); (M.T.); (K.L.); (A.A.)
| | - Nihad Abbas
- NMC Royal Hospital, Abu Dhabi P.O. Box 35233, United Arab Emirates; (S.A.); (N.A.); (K.A.); (S.K.); (A.A.); (S.R.R.); (M.A.); (S.A.); (H.S.); (M.T.); (K.L.); (A.A.)
| | - Kamran Ahmed
- NMC Royal Hospital, Abu Dhabi P.O. Box 35233, United Arab Emirates; (S.A.); (N.A.); (K.A.); (S.K.); (A.A.); (S.R.R.); (M.A.); (S.A.); (H.S.); (M.T.); (K.L.); (A.A.)
| | - Samera Kamran
- NMC Royal Hospital, Abu Dhabi P.O. Box 35233, United Arab Emirates; (S.A.); (N.A.); (K.A.); (S.K.); (A.A.); (S.R.R.); (M.A.); (S.A.); (H.S.); (M.T.); (K.L.); (A.A.)
| | - Arun Arya
- NMC Royal Hospital, Abu Dhabi P.O. Box 35233, United Arab Emirates; (S.A.); (N.A.); (K.A.); (S.K.); (A.A.); (S.R.R.); (M.A.); (S.A.); (H.S.); (M.T.); (K.L.); (A.A.)
| | - Srinivasa Raghu Rao
- NMC Royal Hospital, Abu Dhabi P.O. Box 35233, United Arab Emirates; (S.A.); (N.A.); (K.A.); (S.K.); (A.A.); (S.R.R.); (M.A.); (S.A.); (H.S.); (M.T.); (K.L.); (A.A.)
| | - Mahmoud Abdelshakor
- NMC Royal Hospital, Abu Dhabi P.O. Box 35233, United Arab Emirates; (S.A.); (N.A.); (K.A.); (S.K.); (A.A.); (S.R.R.); (M.A.); (S.A.); (H.S.); (M.T.); (K.L.); (A.A.)
| | - Sara Ali
- NMC Royal Hospital, Abu Dhabi P.O. Box 35233, United Arab Emirates; (S.A.); (N.A.); (K.A.); (S.K.); (A.A.); (S.R.R.); (M.A.); (S.A.); (H.S.); (M.T.); (K.L.); (A.A.)
| | - Honeymol Sebastian
- NMC Royal Hospital, Abu Dhabi P.O. Box 35233, United Arab Emirates; (S.A.); (N.A.); (K.A.); (S.K.); (A.A.); (S.R.R.); (M.A.); (S.A.); (H.S.); (M.T.); (K.L.); (A.A.)
| | - Mishal Tariq
- NMC Royal Hospital, Abu Dhabi P.O. Box 35233, United Arab Emirates; (S.A.); (N.A.); (K.A.); (S.K.); (A.A.); (S.R.R.); (M.A.); (S.A.); (H.S.); (M.T.); (K.L.); (A.A.)
| | - Kumar Lal
- NMC Royal Hospital, Abu Dhabi P.O. Box 35233, United Arab Emirates; (S.A.); (N.A.); (K.A.); (S.K.); (A.A.); (S.R.R.); (M.A.); (S.A.); (H.S.); (M.T.); (K.L.); (A.A.)
| | - Ahmed Abdelrahman
- NMC Royal Hospital, Abu Dhabi P.O. Box 35233, United Arab Emirates; (S.A.); (N.A.); (K.A.); (S.K.); (A.A.); (S.R.R.); (M.A.); (S.A.); (H.S.); (M.T.); (K.L.); (A.A.)
- Internal Medicine Department, Zagazig School of Medicine, Zagazig 44519, Egypt
| |
Collapse
|
18
|
Ristovska E, Bojadjieva ТM, Velkova Е, Dimceva АH, Todorovski B, Tashkovska M, Rastvorceva RG, Bosevski M. Rare Blood Groups in ABO, Rh, Kell Systems - Biological and Clinical Significance. Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2022; 43:77-87. [PMID: 35843921 DOI: 10.2478/prilozi-2022-0021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Background: The frequency of ABO, Rh and Kell blood group antigens differs among populations of different ethnic ancestry. There are low-frequency antigens (<1%) and high-frequency antigens (>90%). A rare blood group is defined as the absence of a high-frequency antigen in the general population, as well as absence of multiple frequent antigens within a single or multiple blood group systems. Aim: To perform red blood cell typing and to calculate the antigen and phenotype frequencies, in order to identify rare blood group donors within the clinically most important АВО, Rh and Kell systems. Material and Methods: АВО, Rh (D, C, E, c, e) and Kell (K) antigen typing was performed using specific monoclonal sera and microplate technique, while Cellano (k) typing was performed with a monoclonal anti-k, antihuman globulin and column agglutination technique. Weak ABO subgroups were determined using the absorption elution method or molecular genotyping (PCR-SSP). Results: ABO antigen frequency is: A (40.89%), O (34.22%), B (16.97%), AB (7.92%) and weak ABO subgroups (0, 009 %). The established genotypes were AxO1 (0, 0026%) and AxB (0, 001%). Rh antigen frequency is: D (85.79%), C (71.7%), c (76.0%), E (26.0%) and е (97.95%). The most common Rh pheno-type is the DCcee (32.7%) while the rarest phenotype is the DCCEE phenotype (0. 003%). The prevalence of K and k antigen is 7.5% and 99.94%, respectively. The frequency of the rare phenotype K+k- is 0.06%. Conclusion: Large scale phenotyping of blood group antigens enables the identification of blood donors with rare blood groups for patients with rare phenotypes or with antibodies to high-frequency antigens and to frequent antigens within one or more blood group systems.
Collapse
Affiliation(s)
- Elena Ristovska
- Institute for transfusion medicine, St Cyril and Methodius University, Medical Faculty, Skopje, RN Macedonia
| | | | - Еmilija Velkova
- Institute for transfusion medicine, St Cyril and Methodius University, Medical Faculty, Skopje, RN Macedonia
| | - Аnita Hristova Dimceva
- Institute for transfusion medicine, St Cyril and Methodius University, Medical Faculty, Skopje, RN Macedonia
| | - Bojan Todorovski
- Institute for transfusion medicine, St Cyril and Methodius University, Medical Faculty, Skopje, RN Macedonia
| | - Marija Tashkovska
- Institute for transfusion medicine, St Cyril and Methodius University, Medical Faculty, Skopje, RN Macedonia
| | - Rada Grubovic Rastvorceva
- Institute for transfusion medicine, St Cyril and Methodius University, Medical Faculty, Skopje, RN Macedonia
| | - Marijan Bosevski
- Clinic of cardiology, St Cyril and Methodius University, Medical Faculty, Skopje, RN Macedonia
| |
Collapse
|
19
|
A Pilot Study on COVID-19 Positive Subjects: An Excerpt of Post-Infection-Pro-Diabetic Disposition & Related Consequences in Correlation to Hepato-Pancreatic Bio-Markers, Pro-Inflammatory Cytokines and Other Risk Factors. Indian J Clin Biochem 2022; 38:182-192. [PMID: 35756691 PMCID: PMC9206463 DOI: 10.1007/s12291-022-01054-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Accepted: 05/18/2022] [Indexed: 01/08/2023]
Abstract
COVID-19, a global pandemic that led to increased morbidity and mortality worldwide since its outcome at the end of the year 2019. A newly discovered variant of severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-2) was the arbitrator for spreading the syndrome by droplet transmission causing multi-organ failure in many occasions. A post-infection-pro-diabetic disposition was found evident in this study with the persistence of hepato-pancreatic aberrations in respect of reference range of tissue specific bio-markers in hospital admitted COVID-19 cases. The results of this study show that hyperglycemia is a risk factor in precipitating disease oriented complications to the patients with COVID-19 disease. A post-infection follow- up on glycemic-index and related complexities is a vital need to the COVID-19 infected convalescent subjects. Implementation of guidelines on social measure and awareness of anti-viral interventions may be the only way to prevent COVID-19 transmission.
Collapse
|
20
|
Enguita-Germán M, Librero J, Leache L, Gutiérrez-Valencia M, Tamayo I, Jericó C, Gorricho J, García-Erce JA. Role of the AB0 blood group in COVID-19 infection and complications: A population-based study. Transfus Apher Sci 2022; 61:103357. [PMID: 35148968 PMCID: PMC8762836 DOI: 10.1016/j.transci.2022.103357] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2021] [Revised: 01/05/2022] [Accepted: 01/15/2022] [Indexed: 12/16/2022]
Abstract
Since the beginning of the COVID-19 pandemic, the ABO blood group has been described as a possible biological marker of susceptibility for the disease. This study evaluates the role of ABO group on the risk of SARS-CoV-2 infection and related complications in a population-based cohort including 87,090 subjects from the Navarre population (Northern Spain) with no history of SARS-CoV-2 infection and with known ABO blood group, after one year of the pandemic (May 2020 - May 2021). The risk of infection, hospitalization, Intensive Care Unit (ICU) admission and death was analyzed using multivariate logistic regression, adjusting for possible confounding variables. A lower risk of infection was observed in group 0 vs non-0 groups [OR 0.94 (95 %CI 0.90-0.99)], a higher risk of infection in group A vs non-A groups [OR 1.09 (95 %CI 1.04-1.15)] and a higher risk of infection in group A vs group 0 [OR 1.08 (95CI 1.03-1.14)] (when the 4 groups are analyzed separately). No association was observed between blood groups and hospitalization, ICU admission, or death in SARS-CoV-2 infected subjects. Regarding the risk of SARS-CoV-2 infection, we observed a protective role of group O and a greater risk in the A group.
Collapse
Affiliation(s)
- Mónica Enguita-Germán
- Unidad de Metodología. Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain; Red de Investigación en Servicios Sanitarios y Enfermedades Crónicas (REDISSEC), Bilbao, Spain.
| | - Julián Librero
- Unidad de Metodología. Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain; Red de Investigación en Servicios Sanitarios y Enfermedades Crónicas (REDISSEC), Bilbao, Spain.
| | - Leire Leache
- Sección de Innovación y Organización, Servicio Navarro de Salud-Osasunbidea, Spain.
| | | | - Ibai Tamayo
- Unidad de Metodología. Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain; Red de Investigación en Servicios Sanitarios y Enfermedades Crónicas (REDISSEC), Bilbao, Spain.
| | - Carlos Jericó
- Department of Internal Medicine, Hospital Sant Joan Despí-Moisès Broggi, Consorci Sanitari Integral, Sant Joan Despí, Barcelona, Spain.
| | - Javier Gorricho
- Servicios de Evaluación y Difusión de Resultados, Servicio Navarro de Salud-Osasunbidea, Spain.
| | - José Antonio García-Erce
- Banco de Sangre y Tejidos de Navarra, Servicio Navarro de Salud, Osasunbidea, Pamplona, Spain; Grupo Español de Rehabilitación Multimodal (GERM), Instituto Aragonés de Ciencias de la Salud, Zaragoza, Spain; Grupo idiPAZ de «Investigación en PBM», Madrid, Spain.
| |
Collapse
|
21
|
Gurung S, Mahotra NB, Shrestha L, Sherpali A, Joshi SP, Shrestha G, Shrestha S, Shakya A, Kandel M. Association of ABO blood group with susceptibility to SARS-CoV-2 infection in Rupandehi district of Nepal. SAGE Open Med 2022; 10:20503121221095413. [PMID: 35509956 PMCID: PMC9058330 DOI: 10.1177/20503121221095413] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2022] [Accepted: 04/01/2022] [Indexed: 12/21/2022] Open
Abstract
Objectives: Recent studies after the outbreak of coronavirus disease 2019 have shown an association of the ABO blood group to the susceptibility of severe acute respiratory syndrome coronavirus 2 infection. Anti-A and anti-B antibodies, carbohydrate clustering, interleukin-6 levels and host transmembrane protease serine subtype 2 were suggested to cause the variable susceptibility of severe acute respiratory syndrome coronavirus 2 infection to the ABO blood groups. This study aims to find the association of the ABO blood group with severe acute respiratory syndrome coronavirus 2 infection susceptibility in Nepal. Methods: Population-based matched case–control study was conducted from October 2021 to February 2022 in Rupandehi district of Nepal. A total of 1091 reverse transcription-polymerase chain reaction confirmed coronavirus disease 2019 cases and 2182 controls were included in the study by convenient sampling method. Results: A statistically significant association of severe acute respiratory syndrome coronavirus 2 infection was observed for the blood group AB between cases and controls (11.5% vs 8.5%; odds ratio = 1.4, 95% confidence interval = 1.10–1.78). However, there was no association of severe acute respiratory syndrome coronavirus 2 infection for blood group A (26.7% vs 28.23%; odds ratio = 0.93, 95% confidence interval = 0.79–1.09), B (26.9% vs 29.84%; odds ratio = 0.86, 95% confidence interval = 0.73–1.02) and O (34.9% vs 33.41%; odds ratio = 1.07, 95% confidence interval = 0.92–1.25). Conclusion: This study reported slightly more susceptibility to severe acute respiratory syndrome coronavirus 2 infection among individuals with blood group AB.
Collapse
Affiliation(s)
- Sanyukta Gurung
- Department of Clinical Physiology, Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University, Kathmandu, Nepal
| | - Narayan Bahadur Mahotra
- Department of Clinical Physiology, Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University, Kathmandu, Nepal
- Narayan Bahadur Mahotra, Department of Clinical Physiology, Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University, Maharajgunj Road, Kathmandu 44600, Nepal.
| | - Lava Shrestha
- Department of Clinical Physiology, Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University, Kathmandu, Nepal
| | - Aakash Sherpali
- Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University, Kathmandu, Nepal
| | - Surya Prakash Joshi
- Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University, Kathmandu, Nepal
| | - Gambhir Shrestha
- Department of Community Medicine, Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University, Kathmandu, Nepal
| | - Shailesh Shrestha
- Department of Clinical Psychology, Tri-Chandra College, Tribhuvan University, Kathmandu, Nepal
| | - Aman Shakya
- Department of Clinical Physiology, Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University, Kathmandu, Nepal
| | - Manoj Kandel
- Department of Biomedical Engineering and Environmental Science, National Tsing Hua University, Hsinchu
| |
Collapse
|
22
|
The rs8176740 T/A and rs512770 T/C Genetic Variants of the ABO Gene Increased the Risk of COVID-19, as well as the Plasma Concentration Platelets. Biomolecules 2022; 12:biom12040486. [PMID: 35454075 PMCID: PMC9027896 DOI: 10.3390/biom12040486] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Revised: 03/20/2022] [Accepted: 03/21/2022] [Indexed: 02/01/2023] Open
Abstract
We conducted a case-control study in order to evaluate whether ABO gene polymorphisms were associated with a high risk of developing COVID-19 in a cohort of patients. Six ABO gene polymorphisms (rs651007 T/C, rs579459 T/C, rs495828 T/G, rs8176746 A/C, rs8176740 T/A, and rs512770 T/C) were determined using TaqMan genotyping assays in a group of 415 COVID-19 patients and 288 healthy controls. The distribution of rs651007 T/C, rs579459 T/C, rs495828 T/G, and rs8176746 A/C polymorphisms was similar in patients and healthy controls. Nonetheless, under co-dominant (OR = 1.89, pCCo-dominant = 6 × 10−6), recessive (OR = 1.98, pCRecessive = 1 × 10−4), and additive (OR = 1.36, pCAdditive = 3 × 10−3) models, the TT genotype of the rs8176740 T/A polymorphism increased the risk of developing COVID-19. In the same way, under co-dominant, recessive, and additive models, the TT genotype of the rs512770 T/C polymorphism was associated with a high risk of developing COVID-19 (OR = 1.87, pCCo-dominant = 2 × 10−3; OR = 1.87, pCRecessive = 5 × 10−4; and OR = 1.35, pCAdditive = 4 × 10−3, respectively). On the other hand, the GTC and GAT haplotypes were associated with a high risk of COVID-19 (OR = 5.45, pC = 1 × 10−6 and OR = 6.33, pC = 1 × 10−6, respectively). In addition, the rs8176740 TT genotype was associated with high-platelet plasma concentrations in patients with COVID-19. Our data suggested that the ABO rs512770 T/C and rs8176740 T/A polymorphisms increased the risk of developing COVID-19 and the plasma concentration of platelets.
Collapse
|
23
|
Amri N, Bégin R, Tessier N, Vachon L, Villeneuve L, Bégin P, Bazin R, Loubaki L, Martel C. Use of Early Donated COVID-19 Convalescent Plasma Is Optimal to Preserve the Integrity of Lymphatic Endothelial Cells. Pharmaceuticals (Basel) 2022; 15:ph15030365. [PMID: 35337162 PMCID: PMC8948637 DOI: 10.3390/ph15030365] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2022] [Revised: 03/11/2022] [Accepted: 03/16/2022] [Indexed: 01/27/2023] Open
Abstract
Convalescent plasma therapy (CPT) has gained significant attention since the onset of the coronavirus disease 2019 (COVID-19) pandemic. However, clinical trials designed to study the efficacy of CPT based on antibody concentrations were inconclusive. Lymphatic transport is at the interplay between the immune response and the resolution of inflammation from peripheral tissues, including the artery wall. As vascular complications are a key pathogenic mechanism in COVID-19, leading to inflammation and multiple organ failure, we believe that sustaining lymphatic vessel function should be considered to define optimal CPT. We herein sought to determine what specific COVID-19 convalescent plasma (CCP) characteristics should be considered to limit inflammation-driven lymphatic endothelial cells (LEC) dysfunction. CCP donated 16 to 100 days after the last day of symptoms was characterized and incubated on inflammation-elicited adult human dermal LEC (aHDLEC). Plasma analysis revealed that late donation correlates with higher concentration of circulating pro-inflammatory cytokines. Conversely, extracellular vesicles (EVs) derived from LEC are more abundant in early donated plasma (r = −0.413, p = 0.004). Thus, secretion of LEC-EVs by an impaired endothelium could be an alarm signal that instigate the self-defense of peripheral lymphatic vessels against an excessive inflammation. Indeed, in vitro experiments suggest that CCP obtained rapidly following the onset of symptoms does not damage the aHDLEC junctions as much as late-donated plasma. We identified a particular signature of CCP that would counteract the effects of an excessive inflammation on the lymphatic endothelium. Accordingly, an easy and efficient selection of convalescent plasma based on time of donation would be essential to promote the preservation of the lymphatic and immune system of infected patients.
Collapse
Affiliation(s)
- Nada Amri
- Faculty of Medicine, Université de Montréal, Pavillon Roger-Gaudry, 2900 Edouard Montpetit Blvd, Montreal, QC H3T 1J4, Canada; (N.A.); (R.B.); (N.T.); (L.V.)
- Montreal Heart Institute, 5000 Belanger Street, Montreal, QC H1T 1C8, Canada;
| | - Rémi Bégin
- Faculty of Medicine, Université de Montréal, Pavillon Roger-Gaudry, 2900 Edouard Montpetit Blvd, Montreal, QC H3T 1J4, Canada; (N.A.); (R.B.); (N.T.); (L.V.)
- Montreal Heart Institute, 5000 Belanger Street, Montreal, QC H1T 1C8, Canada;
| | - Nolwenn Tessier
- Faculty of Medicine, Université de Montréal, Pavillon Roger-Gaudry, 2900 Edouard Montpetit Blvd, Montreal, QC H3T 1J4, Canada; (N.A.); (R.B.); (N.T.); (L.V.)
- Montreal Heart Institute, 5000 Belanger Street, Montreal, QC H1T 1C8, Canada;
| | - Laurent Vachon
- Faculty of Medicine, Université de Montréal, Pavillon Roger-Gaudry, 2900 Edouard Montpetit Blvd, Montreal, QC H3T 1J4, Canada; (N.A.); (R.B.); (N.T.); (L.V.)
- Montreal Heart Institute, 5000 Belanger Street, Montreal, QC H1T 1C8, Canada;
| | - Louis Villeneuve
- Montreal Heart Institute, 5000 Belanger Street, Montreal, QC H1T 1C8, Canada;
| | - Philippe Bégin
- Department of Pediatrics, CHU Sainte-Justine, 3175 Chem. de la Côte-Sainte-Catherine, Montreal, QC H3T 1C5, Canada;
- Department of Medicine, Centre Hospitalier de l’Université de Montréal, 900 Rue Saint-Denis, Montreal, QC H2X 0A9, Canada
| | - Renée Bazin
- Medical Affairs and Innovation, Héma-Québec, 1070 Avenue des Sciences-de-la-Vie, Québec, QC G1V 5C3, Canada; (R.B.); (L.L.)
| | - Lionel Loubaki
- Medical Affairs and Innovation, Héma-Québec, 1070 Avenue des Sciences-de-la-Vie, Québec, QC G1V 5C3, Canada; (R.B.); (L.L.)
| | - Catherine Martel
- Faculty of Medicine, Université de Montréal, Pavillon Roger-Gaudry, 2900 Edouard Montpetit Blvd, Montreal, QC H3T 1J4, Canada; (N.A.); (R.B.); (N.T.); (L.V.)
- Montreal Heart Institute, 5000 Belanger Street, Montreal, QC H1T 1C8, Canada;
- Correspondence: ; Tel.: +1-(514)-376-3330 (ext. 2977)
| |
Collapse
|
24
|
Mariam SH. The Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Pandemic: Are Africa's Prevalence and Mortality Rates Relatively Low? Adv Virol 2022; 2022:3387784. [PMID: 35256885 PMCID: PMC8898136 DOI: 10.1155/2022/3387784] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2021] [Revised: 01/14/2022] [Accepted: 01/28/2022] [Indexed: 12/13/2022] Open
Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of coronavirus disease 19 (COVID-19), has been rapidly spreading since December 2019, and within a few months, it turned out to be a global pandemic. The disease affects primarily the lungs, but its pathogenesis spreads to other organs as well. However, its mortality rates vary, and in the majority of infected people, there are no serious consequences. Many factors including advanced age, preexisting health conditions, and genetic predispositions are believed to exacerbate outcomes of COVID-19. The virus contains several structural proteins including the spike (S) protein with subunits for binding, fusion, and internalization into host cells following interaction with host cell receptors and proteases (ACE2 and TMPRSS2, respectively) to cause the subsequent pathology. Although the pandemic has spread into all countries, most of Africa is thought of as having relatively less prevalence and mortality. Several hypotheses have been forwarded as reasons for this and include warmer weather conditions, vaccination with BCG (i.e., trained immunity), and previous malaria infection. From genetics or metabolic points of view, it has been proposed that most African populations could be protected to some degree because they lack some genetic susceptibility risk factors or have low-level expression of allelic variants, such as ACE2 and TMPRSS2 that are thought to be involved in increased infection risk or disease severity. The frequency of occurrence of α-1 antitrypsin (an inhibitor of a tissue-degrading protease, thereby protecting target host tissues including the lung) deficiency is also reported to be low in most African populations. More recently, infections in Africa appear to be on the rise. In general, there are few studies on the epidemiology and pathogenesis of the disease in African contexts, and the overall costs and human life losses due to the pandemic in Africa will be determined by all factors and conditions interacting in complex ways.
Collapse
Affiliation(s)
- Solomon H. Mariam
- Infectious Diseases Program, Aklilu Lemma Institute of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia
| |
Collapse
|
25
|
Andreakos E, Abel L, Vinh DC, Kaja E, Drolet BA, Zhang Q, O'Farrelly C, Novelli G, Rodríguez-Gallego C, Haerynck F, Prando C, Pujol A, Su HC, Casanova JL, Spaan AN. A global effort to dissect the human genetic basis of resistance to SARS-CoV-2 infection. Nat Immunol 2022; 23:159-164. [PMID: 34667308 PMCID: PMC8524403 DOI: 10.1038/s41590-021-01030-z] [Citation(s) in RCA: 37] [Impact Index Per Article: 18.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2021] [Accepted: 08/12/2021] [Indexed: 11/17/2022]
Abstract
SARS-CoV-2 infections display tremendous interindividual variability, ranging from asymptomatic infections to life-threatening disease. Inborn errors of, and autoantibodies directed against, type I interferons (IFNs) account for about 20% of critical COVID-19 cases among SARS-CoV-2-infected individuals. By contrast, the genetic and immunological determinants of resistance to infection per se remain unknown. Following the discovery that autosomal recessive deficiency in the DARC chemokine receptor confers resistance to Plasmodium vivax, autosomal recessive deficiencies of chemokine receptor 5 (CCR5) and the enzyme FUT2 were shown to underlie resistance to HIV-1 and noroviruses, respectively. Along the same lines, we propose a strategy for identifying, recruiting, and genetically analyzing individuals who are naturally resistant to SARS-CoV-2 infection.
Collapse
Grants
- UM1 HG006504 NHGRI NIH HHS
- UL1 TR001863 NCATS NIH HHS
- UL1 TR001866 NCATS NIH HHS
- R01 AI088364 NIAID NIH HHS
- R01 AI163029 NIAID NIH HHS
- U24 HG008956 NHGRI NIH HHS
- European Union’s Horizon 2020 research and innovation program (Marie Sklodowska-Curie grant No. 789645)
- European Commission’s Horizon 2020 research and innovation program (IMMUNAID, grant No. 779295, CURE, grant No. 767015 and TO_AITION grant No. 848146) and the Hellenic Foundation for Research and Innovation (INTERFLU, no. 1574)
- National Institutes of Health (NIH) (R01AI088364), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1TR001866), a Fast Grant from Emergent Ventures, Mercatus Center at George Mason University, the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the Fisher Center for Alzheimer’s Research Foundation, the Meyer Foundation, the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the FRM and ANR GENCOVID project (ANR-20-COVI-0003), ANRS-COV05, the Fondation du Souffle, the Square Foundation, Grandir - Fonds de solidarité pour l’enfance, the SCOR Corporate Foundation for Science, the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, Institut National de la Santé et de la Recherche Médicale (INSERM) and the University of Paris
- Science Foundation Ireland COVID-19 Program
- Regione Lazio (Research Group Projects 2020) No. A0375-2020-36663, GecoBiomark
- Horizon 2020 program grant no. 824110 (EasiGenomics grant no. COVID-19/PID12342) and CERCA Program/Generalitat de Catalunya
- Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health
Collapse
Affiliation(s)
- Evangelos Andreakos
- Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
| | - Laurent Abel
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France
- University of Paris, Imagine Institute, Paris, France
| | - Donald C Vinh
- Department of Medicine, Division of Infectious Diseases, McGill University Health Centre, Montréal, Québec, Canada
- Infectious Disease Susceptibility Program, Research Institute, McGill University Health Centre, Montréal, Québec, Canada
| | | | - Beth A Drolet
- Department of Dermatology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA
| | - Qian Zhang
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France
- University of Paris, Imagine Institute, Paris, France
| | - Cliona O'Farrelly
- Comparative Immunology Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland
| | - Giuseppe Novelli
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
| | - Carlos Rodríguez-Gallego
- Department of Immunology, Hospital Universitario de Gran Canaria Dr. Negrín, Canarian Health System, Las Palmas de Gran Canaria, Las Palmas, Spain
- Department of Clinical Sciences, University Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Las Palmas, Spain
| | - Filomeen Haerynck
- Department of Pediatric Immunology and Pulmonology, Centre for Primary Immunodeficiency Ghent (CPIG), PID Research Laboratory, Jeffrey Modell Diagnosis and Research Centre, Ghent University Hospital, Ghent, Belgium
| | - Carolina Prando
- Faculdades Pequeno Príncipe, Instituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, Brazil
| | - Aurora Pujol
- Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
- Catalan Institution of Research and Advanced Studies (ICREA), Barcelona, Spain
- Center for Biomedical Research on Rare Diseases U759 (CIBERER), ISCIII, Barcelona, Spain
| | - Helen C Su
- Intramural Research Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| | - Jean-Laurent Casanova
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France
- University of Paris, Imagine Institute, Paris, France
- Howard Hughes Medical Institute, New York, NY, USA
| | - András N Spaan
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.
- Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands.
| |
Collapse
|
26
|
Cavezzi A, Menicagli R, Troiani E, Corrao S. COVID-19, Cation Dysmetabolism, Sialic Acid, CD147, ACE2, Viroporins, Hepcidin and Ferroptosis: A Possible Unifying Hypothesis. F1000Res 2022; 11:102. [PMID: 35340277 PMCID: PMC8921693 DOI: 10.12688/f1000research.108667.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 01/20/2022] [Indexed: 08/26/2024] Open
Abstract
Background: iron and calcium dysmetabolism, with hyperferritinemia, hypoferremia, hypocalcemia and anemia have been documented in the majority of COVID-19 patients at later/worse stages. Furthermore, complementary to ACE2, both sialic acid (SA) molecules and CD147 proved relevant host receptors for SARS-CoV-2 entry, which explains the viral attack to multiple types of cells, including erythrocytes, endothelium and neural tissue. Several authors advocated that cell ferroptosis may be the core and final cell degenerative mechanism. Methods: a literature research was performed in several scientific search engines, such as PubMed Central, Cochrane Library, Chemical Abstract Service. More than 500 articles were retrieved until mid-December 2021, to highlight the available evidence about the investigated issues. Results: based on COVID-19 literature data, we have highlighted a few pathophysiological mechanisms, associated with virus-based cation dysmetabolism, multi-organ attack, mitochondria degeneration and ferroptosis. Our suggested elucidated pathological sequence is: a) spike protein subunit S1 docking with sialylated membrane glycoproteins/receptors (ACE2, CD147), and S2 subunit fusion with the lipid layer; b) cell membrane morpho-functional changes due to the consequent electro-chemical variations and viroporin action, which induce an altered ion channel function and intracellular cation accumulation; c) additional intracellular iron concentration due to a deregulated hepcidin-ferroportin axis, with higher hepcidin levels. Viral invasion may also affect erythrocytes/erythroid precursors, endothelial cells and macrophages, through SA and CD147 receptors, with relative hemoglobin and iron/calcium dysmetabolism. AB0 blood group, hemochromatosis, or environmental elements may represent possible factors which affect individual susceptibility to COVID-19. Conclusions: our literature analysis confirms the combined role of SA molecules, ACE2, CD147, viroporins and hepcidin in determining the cation dysmetabolism and final ferroptosis in the cells infected by SARS-CoV-2. The altered ion channels and electrochemical gradients of the cell membrane have a pivotal role in the virus entry and cell dysmetabolism, with subsequent multi-organ immune-inflammatory degeneration and erythrocyte/hemoglobin alterations.
Collapse
Affiliation(s)
- Attilio Cavezzi
- Eurocenter Venalinfa, San Benedetto del Tronto, AP, 63074, Italy
| | | | - Emidio Troiani
- Cardiology Unit, Social Security Institute, State Hospital, Cailungo, 47893, San Marino
| | - Salvatore Corrao
- Department of Clinical Medicine, Internal Medicine Division,, ARNAS Civico Di Cristina Benfratelli Hospital Trust, Palermo, Italy
| |
Collapse
|
27
|
Cavezzi A, Menicagli R, Troiani E, Corrao S. COVID-19, Cation Dysmetabolism, Sialic Acid, CD147, ACE2, Viroporins, Hepcidin and Ferroptosis: A Possible Unifying Hypothesis. F1000Res 2022; 11:102. [PMID: 35340277 PMCID: PMC8921693 DOI: 10.12688/f1000research.108667.2] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 02/17/2022] [Indexed: 12/15/2022] Open
Abstract
Background: iron and calcium dysmetabolism, with hyperferritinemia, hypoferremia, hypocalcemia and anemia have been documented in the majority of COVID-19 patients at later/worse stages. Furthermore, complementary to ACE2, both sialic acid (SA) molecules and CD147 proved relevant host receptors for SARS-CoV-2 entry, which explains the viral attack to multiple types of cells, including erythrocytes, endothelium and neural tissue. Several authors advocated that cell ferroptosis may be the core and final cell degenerative mechanism. Methods: a literature research was performed in several scientific search engines, such as PubMed Central, Cochrane Library, Chemical Abstract Service. More than 500 articles were retrieved until mid-December 2021, to highlight the available evidence about the investigated issues. Results: based on COVID-19 literature data, we have highlighted a few pathophysiological mechanisms, associated with virus-based cation dysmetabolism, multi-organ attack, mitochondria degeneration and ferroptosis. Our suggested elucidated pathological sequence is: a) spike protein subunit S1 docking with sialylated membrane glycoproteins/receptors (ACE2, CD147), and S2 subunit fusion with the lipid layer; b) cell membrane morpho-functional changes due to the consequent electro-chemical variations and viroporin action, which induce an altered ion channel function and intracellular cation accumulation; c) additional intracellular iron concentration due to a deregulated hepcidin-ferroportin axis, with higher hepcidin levels. Viral invasion may also affect erythrocytes/erythroid precursors, endothelial cells and macrophages, through SA and CD147 receptors, with relative hemoglobin and iron/calcium dysmetabolism. AB0 blood group, hemochromatosis, or environmental elements may represent possible factors which affect individual susceptibility to COVID-19. Conclusions: our literature analysis confirms the combined role of SA molecules, ACE2, CD147, viroporins and hepcidin in determining the cation dysmetabolism and final ferroptosis in the cells infected by SARS-CoV-2. The altered ion channels and electrochemical gradients of the cell membrane have a pivotal role in the virus entry and cell dysmetabolism, with subsequent multi-organ immune-inflammatory degeneration and erythrocyte/hemoglobin alterations.
Collapse
Affiliation(s)
- Attilio Cavezzi
- Eurocenter Venalinfa, San Benedetto del Tronto, AP, 63074, Italy
| | | | - Emidio Troiani
- Cardiology Unit, Social Security Institute, State Hospital, Cailungo, 47893, San Marino
| | - Salvatore Corrao
- Department of Clinical Medicine, Internal Medicine Division,, ARNAS Civico Di Cristina Benfratelli Hospital Trust, Palermo, Italy
| |
Collapse
|
28
|
Boukhari R, Breiman A, Jazat J, Ruvoën-Clouet N, Martinez S, Damais-Cepitelli A, Le Niger C, Devie-Hubert I, Penasse F, Mauriere D, Sébille V, Dürrbach A, Le Pendu J. ABO Blood Group Incompatibility Protects Against SARS-CoV-2 Transmission. Front Microbiol 2022; 12:799519. [PMID: 35069504 PMCID: PMC8767008 DOI: 10.3389/fmicb.2021.799519] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2021] [Accepted: 11/30/2021] [Indexed: 12/19/2022] Open
Abstract
ABO blood groups appear to be associated with the risk of SARS-CoV-2 infection, but the underlying mechanisms and their real importance remain unclear. Two hypotheses have been proposed: ABO compatibility-dependence (neutralization by anti-ABO antibodies) and ABO-dependent intrinsic susceptibility (spike protein attachment to histo-blood group glycans). We tested the first hypothesis through an anonymous questionnaire addressed to hospital staff members. We estimated symptomatic secondary attack rates (SAR) for 333 index cases according to spouse ABO blood group compatibility. Incompatibility was associated with a lower SAR (28% vs. 47%; OR 0.43, 95% CI 0.27–0.69), but no ABO dependence was detected in compatible situations. For the second hypothesis, we detected no binding of recombinant SARS-CoV-2 RBD to blood group-containing glycans. Thus, although no intrinsic differences in susceptibility according to ABO blood type were detected, ABO incompatibility strongly decreased the risk of COVID-19 transmission, suggesting that anti-ABO antibodies contribute to virus neutralization.
Collapse
Affiliation(s)
| | - Adrien Breiman
- CHU de Nantes, Nantes, France.,Université de Nantes, Inserm, CRCINA, Nantes, France
| | | | - Nathalie Ruvoën-Clouet
- Université de Nantes, Inserm, CRCINA, Nantes, France.,Oniris, Ecole Nationale Vétérinaire, Agroalimentaire et de l'Alimentation, Nantes, France
| | | | | | | | | | - Fanny Penasse
- Service Pharmacie, CH Bar sur Aube, Bar sur Aube, France
| | | | - Véronique Sébille
- Methodology and Biostatitics Unit, CHU de Nantes, Nantes, France.,Université de Nantes, Université de Tours, Inserm, SPHERE U1246, Nantes, France
| | - Antoine Dürrbach
- Service Néphrologie-Dialyse-Transplantation, CHU Henri Mondor, Inserm, UMR 1186, Institut Gustave Roussy, Université Paris Saclay, Créteil, France
| | | |
Collapse
|
29
|
Adli A, Rahimi M, Khodaie R, Hashemzaei N, Hosseini SM. Role of Genetic Variants and Host Polymorphisms on COVID‐19: From Viral Entrance Mechanisms to Immunological Reactions. J Med Virol 2022; 94:1846-1865. [PMID: 35076118 PMCID: PMC9015257 DOI: 10.1002/jmv.27615] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2021] [Revised: 01/04/2022] [Accepted: 01/18/2022] [Indexed: 11/24/2022]
Abstract
Coronavirus disease 2019 (COVID‐19), caused by a highly pathogenic emerging virus, is called severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Knowledge regarding the pathogenesis of this virus is in infancy; however, investigation on the pathogenic mechanisms of the SARS‐CoV‐2 is underway. In COVID‐19, one of the most remarkable characteristics is the wide range of disease manifestation and severity seen across individuals of different ethnic backgrounds and geographical locations. To effectively manage COVID‐19 in the populations, beyond SARS‐CoV‐2 detection, serological response assessment, and analytic techniques, it is critical to obtain knowledge about at‐risk individuals and comprehend the identified variations in the disease's severity in general and also in the populations' levels. Several factors can contribute to variation in disease presentation, including population density, gender and age differences, and comorbid circumstances including diabetes mellitus, hypertension, and obesity. Genetic factors presumably influence SARS‐CoV‐2 infection susceptibility. Besides this, COVID‐19 has also been linked with a higher risk of mortality in men and certain ethnic groups, revealing that host genetic characteristics may affect the individual risk of death. Also, genetic variants involved in pathologic processes, including virus entrance into cells, antiviral immunity, and inflammatory response, are not entirely understood. Regarding SARS‐CoV‐2 infection characteristics, the present review suggests that various genetic polymorphisms influence virus pathogenicity and host immunity, which might have significant implications for understanding and interpreting the matter of genetics in SARS‐CoV‐2 pathogenicity and customized integrative medical care based on population investigation. Genetic factors presumably influence SARS‐CoV‐2 infection susceptibility. Genetic variants were involved in the pathologic processes of SARS‐CoV‐2 infection. Various genetic polymorphisms influence virus pathogenicity and host immunity. Human leukocyte antigens (HLAs) may play a vital role in SARS‐CoV‐2 susceptibility. Polymorphisms in several genes such as IL‐6, TMPRSS2, IFITM3, CD26, ACE, and DBP were associated with the COVID‐19 severity.
Collapse
Affiliation(s)
- Abolfazl Adli
- Human Genetic Research Center, Baqiyatallah University of Medical SciencesTehran1435916471Iran
| | - Mandana Rahimi
- Department of Pathology, School of Medicine, Hasheminejad Kidney Center, Iran University of Medical SciencesTehranIran
| | - Reza Khodaie
- Department of Biology, East Tehran Branch, Islamic Azad UniversityTehranIran
| | | | - Sayed Mostafa Hosseini
- Human Genetic Research Center, Baqiyatallah University of Medical SciencesTehran1435916471Iran
| |
Collapse
|
30
|
Viral and Host Genetic and Epigenetic Biomarkers Related to SARS-CoV-2 Cell Entry, Infection Rate, and Disease Severity. BIOLOGY 2022; 11:biology11020178. [PMID: 35205046 PMCID: PMC8869311 DOI: 10.3390/biology11020178] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/24/2021] [Revised: 01/14/2022] [Accepted: 01/14/2022] [Indexed: 12/23/2022]
Abstract
The rapid spread of COVID-19 outbreak lead to a global pandemic declared in March 2020. The common features of corona virus family helped to resolve structural characteristics and entry mechanism of SARS-CoV-2. However, rapid mutagenesis leads to the emergence of new strains that may have different reproduction rates or infectivity and may impact the course and severity of the disease. Host related factors may also play a role in the susceptibility for infection as well as the severity and outcomes of the COVID-19. We have performed a literature and database search to summarize potential viral and host-related genomic and epigenomic biomarkers, such as genetic variability, miRNA, and DNA methylation in the molecular pathway of SARS-CoV-2 entry into the host cell, that may be related to COVID-19 susceptibility and severity. Bioinformatics tools may help to predict the effect of mutations in the spike protein on the binding to the ACE2 receptor and the infectivity of the strain. SARS-CoV-2 may also target several transcription factors and tumour suppressor genes, thus influencing the expression of different host genes and affecting cell signalling. In addition, the virus may interfere with RNA expression in host cells by exploiting endogenous miRNA and its viral RNA. Our analysis showed that numerous human miRNA may form duplexes with different coding and non-coding regions of viral RNA. Polymorphisms in human genes responsible for viral entry and replication, as well as in molecular damage response and inflammatory pathways may also contribute to disease prognosis and outcome. Gene ontology analysis shows that proteins encoded by such polymorphic genes are highly interconnected in regulation of defense response. Thus, virus and host related genetic and epigenetic biomarkers may help to predict the course of the disease and the response to treatment.
Collapse
|
31
|
Žiberna K, Jež M, Jazbec K, Mali P, Rahne Potokar U, Rožman P. ABO blood group does not influence the level of anti-SARS-CoV-2 antibodies in convalescent plasma donors. Transfusion 2022; 62:556-562. [PMID: 35041206 DOI: 10.1111/trf.16808] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2021] [Revised: 01/07/2022] [Accepted: 01/07/2022] [Indexed: 11/28/2022]
Abstract
BACKGROUND The association of the ABO blood group with COVID-19 disease has been confirmed by several studies, with the blood group A patients being more susceptible and prone to a more severe clinical course of the disease. Additionally, several authors also addressed the association of ABO-types and the levels of anti-SARS-CoV-2 antibodies in convalescents, mostly supporting a theory that the non-O blood group convalescents present with higher levels of anti-SARS-CoV-2 antibodies. STUDY DESIGN AND METHODS Since previous findings were based on small convalescent cohorts, we quantified the anti-SARS-CoV-2 antibody levels in total 3187 convalescent plasma donors with three commercial serological and one standard neutralizing antibody test. The majority of donors had undergone a mild form of the disease and the median time of sampling was 66 days after diagnosis. RESULTS None of the antibody quantitation results showed any significant association with the ABO blood group types. The same result was evident in the subgroup of vaccinated individuals (n=370) and the subgroups when stratified according to post-COVID-19 periods (0-60, 60-120, and 120-180 days). CONCLUSION In conclusion, we found no evidence to confirm that the ABO blood group types influence the level of SARS-CoV-2 antibody response in COVID-19 convalescent plasma donors.
Collapse
Affiliation(s)
- Klemen Žiberna
- Blood Transfusion Centre of Slovenia, Šlajmerjeva 6, 1000, Ljubljana, Slovenia
| | - Mojca Jež
- Blood Transfusion Centre of Slovenia, Šlajmerjeva 6, 1000, Ljubljana, Slovenia
| | - Katerina Jazbec
- Blood Transfusion Centre of Slovenia, Šlajmerjeva 6, 1000, Ljubljana, Slovenia
| | - Polonca Mali
- Blood Transfusion Centre of Slovenia, Šlajmerjeva 6, 1000, Ljubljana, Slovenia
| | - Urška Rahne Potokar
- Blood Transfusion Centre of Slovenia, Šlajmerjeva 6, 1000, Ljubljana, Slovenia
| | - Primož Rožman
- Blood Transfusion Centre of Slovenia, Šlajmerjeva 6, 1000, Ljubljana, Slovenia
| |
Collapse
|
32
|
Jelinek HF, Mousa M, Alkaabi N, Alefishat E, Daw Elbait G, Kannout H, AlHumaidan H, Selvaraj FA, Imambaccus H, Weber S, Uddin M, Abdulkarim F, Mahboub B, Tay G, Alsafar H. Allelic Variants Within the ABO Blood Group Phenotype Confer Protection Against Critical COVID-19 Hospital Presentation. Front Med (Lausanne) 2022; 8:759648. [PMID: 35096865 PMCID: PMC8793802 DOI: 10.3389/fmed.2021.759648] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2021] [Accepted: 12/13/2021] [Indexed: 12/13/2022] Open
Abstract
Introduction: Coronavirus disease 2019 (COVID-19) disease severity differs widely due to numerous factors including ABO gene-derived susceptibility or resistance. The objective of this study was to investigate the association of the ABO blood group and genetic variations of the ABO gene with COVID-19 severity in a heterogeneous hospital population sample from the United Arab Emirates, with the use of an epidemiological and candidate gene approach from a genome-wide association study (GWAS). Methods: In this cross-sectional study, a total of 646 participants who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were recruited from multiple hospitals and population-based (quarantine camps) recruitment sites from March 2020 to February 2021. The participants were divided into two groups based on the severity of COVID-19: noncritical (n = 453) and critical [intensive care unit (ICU) patients] (n = 193), as per the COVID-19 Reporting and Data System (CO-RADS) classification. The multivariate logistic regression analysis demonstrated the association of ABO blood type as well as circulating anti-A antibodies and anti-B antibodies as well as A and B antigens, in association with critical COVID-19 hospital presentation. A candidate gene analysis approach was conducted from a GWAS where we examined 240 single nucleotide polymorphisms (SNPs) (position in chr9: 136125788-136150617) in the ABO gene, in association with critical COVID-19 hospital presentation. Results: Patients with blood group O [odds ratio (OR): 0.51 (0.33, 0.79); p = 0.003] were less likely to develop critical COVID-19 symptoms. Eight alleles have been identified to be associated with a protective effect of blood group O in ABO 3'untranslated region (UTR): rs199969472 (p = 0.0052), rs34266669 (p = 0.0052), rs76700116 (p = 0.0052), rs7849280 (p = 0.0052), rs34039247 (p = 0.0104), rs10901251 (p = 0.0165), rs9411475 (p = 0.0377), and rs13291798 (p = 0.0377). Conclusion: Our findings suggest that there are novel allelic variants that link genetic variants of the ABO gene and ABO blood groups contributing to the reduced risk of critical COVID-19 disease. This study is the first study to combine genetic and serological evidence of the involvement of the ABO blood groups and the ABO gene allelic associations with COVID-19 severity within the Middle Eastern population.
Collapse
Affiliation(s)
- Herbert F. Jelinek
- Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates
- Department of Biomedical Engineering, College of Engineering, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates
- Center of Heath Engineering Innovation, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates
| | - Mira Mousa
- Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates
- Nuffield Department of Women's and Reproduction Health, Oxford University, Oxford, United Kingdom
| | - Nawal Alkaabi
- Department of Pediatric Infectious Disease, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates
| | - Eman Alefishat
- Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates
- Department of Pharmacology, College of Medicine and Health Sciences, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates
| | - Gihan Daw Elbait
- Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates
| | - Hussein Kannout
- Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates
| | - Hiba AlHumaidan
- Department of Laboratory Medicine Services, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates
| | | | - Hala Imambaccus
- Department of Laboratory Medicine Services, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates
| | - Stefan Weber
- Department of Laboratory Medicine Services, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates
| | - Maimunah Uddin
- Department of Pediatric Infectious Disease, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates
| | - Fatema Abdulkarim
- Dubai Health Authority, Rashid Hospital, Dubai, United Arab Emirates
| | - Bassam Mahboub
- Dubai Health Authority, Rashid Hospital, Dubai, United Arab Emirates
| | - Guan Tay
- Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates
- Division of Psychiatry, Faculty of Health and Medical Sciences, University of Western Australia, Crawley, WA, Australia
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
| | - Habiba Alsafar
- Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates
- Department of Biomedical Engineering, College of Engineering, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates
- Department of Genetics and Molecular Biology, College of Medicine and Health Sciences, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates
| |
Collapse
|
33
|
Baptista FS, Paganoti CF, Gomez UT, Peres SV, Malbouisson LM, Brizot MDL, Francisco RPV. Risk factors for oxygen requirement in hospitalized pregnant and postpartum women with COVID-19. Clinics (Sao Paulo) 2022; 77:100072. [PMID: 35767901 PMCID: PMC9212857 DOI: 10.1016/j.clinsp.2022.100072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/23/2021] [Accepted: 05/23/2022] [Indexed: 01/08/2023] Open
Abstract
OBJECTIVE To identify risk factors for Oxygen (O2) needs in pregnant and postpartum women with COVID-19. METHODS Prospective cohort involving pregnant women hospitalized with COVID-19 from April to October 2020. The oxygen need was analyzed regarding risk factors: demographic characteristics, clinical and laboratory parameters at hospital admission, and chest Computer Tomography (CT) findings. Poisson univariate analysis was used to estimate the Relative Risk (RR) and 95% Confidence Intervals. RESULTS 145 patients, 80 who used and 65 who did not use O2, were included. Body mass index ≥ 30, smoking, and chronic hypertension increased the risk of O2 need by 1.86 (95% CI 1.10-3.21), 1.57 (95% CI 1.16‒2.12), and 1.46 (95% CI 1.09‒1.95), respectively. Patients who were hospitalized for COVID-19 and for obstetric reasons had 8.24 (95% CI 2.8‒24.29) and 3.44 (95% CI 1.05‒11.31) times more use of O2 than those admitted for childbirth and abortion. Respiratory rate ≥ 24 breaths/min and O2 saturation < 95% presented RR for O2 requirements of 2.55 (1.82‒3.56) and 1.68 (95% CI 1.27-2.20), respectively. Ground Glass (GG) < 50% and with GG ≥ 50%, the risk of O2 use were respectively 3.41-fold and 5.33-fold higher than in patients who haven't viral pneumonia on CT. The combination of C-reactive protein ≥ 21 mg/L, hemoglobin < 11.0 g/dL, and lymphopenia < 1500 mm3 on hospital admission increased the risk of O2 use by 4.97-times. CONCLUSIONS In obstetric patients, clinical history, laboratory, clinical and radiological parameters at admission were identified as a risk for O2 need, selecting the population with the greatest chance of worsening.
Collapse
Affiliation(s)
- Fernanda Spadotto Baptista
- Disciplina de Obstetrícia, Departamento de Obstetrícia e Ginecologia, Faculdade de Medicina, Universidade de São Paulo (FMUSP), São Paulo, SP, Brazil.
| | - Cristiane Freitas Paganoti
- Divisão de Clínica Obstétrica, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (HCFMUSP), São Paulo, SP, Brazil
| | - Ursula Trovato Gomez
- Disciplina de Obstetrícia, Departamento de Obstetrícia e Ginecologia, Faculdade de Medicina, Universidade de São Paulo (FMUSP), São Paulo, SP, Brazil
| | - Stela Verzinhasse Peres
- Divisão de Clínica Obstétrica, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (HCFMUSP), São Paulo, SP, Brazil
| | - Luiz Marcelo Malbouisson
- Disciplina de Anestesiologia, Departamento de Cirurgia, Faculdade de Medicina, Universidade de São Paulo (FMUSP), São Paulo, SP, Brazil
| | - Maria de Lourdes Brizot
- Disciplina de Obstetrícia, Departamento de Obstetrícia e Ginecologia, Faculdade de Medicina, Universidade de São Paulo (FMUSP), São Paulo, SP, Brazil
| | - Rossana Pulcineli Vieira Francisco
- Disciplina de Obstetrícia, Departamento de Obstetrícia e Ginecologia, Faculdade de Medicina, Universidade de São Paulo (FMUSP), São Paulo, SP, Brazil
| |
Collapse
|
34
|
Mohamed RGE, Abdallah EI, Muddathir ARM, Aloraini GS, Omer AE, Mangi AA, Eltayeb LB. Differential Leucocytes Count: An Independent Predictor of Clinical Outcomes in SARS-CoV-2 Patients. ARCHIVES OF PHARMACY PRACTICE 2022. [DOI: 10.51847/kh0fira9qm] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
|
35
|
Villalonga-Morales A. Response to the article: Spread of COVID-19 cases in Africa. REVISTA ESPAÑOLA DE ANESTESIOLOGÍA Y REANIMACIÓN (ENGLISH EDITION) 2021; 68:609-610. [PMID: 34857505 PMCID: PMC8612812 DOI: 10.1016/j.redare.2021.04.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 04/24/2021] [Accepted: 04/27/2021] [Indexed: 11/17/2022]
|
36
|
Villalonga-Morales A. África tiene una epidemia de COVID-19 menos intensa. Réplica al artículo: Propagación de casos COVID-19 en África. REVISTA ESPAÑOLA DE ANESTESIOLOGÍA Y REANIMACIÓN 2021; 68:609-610. [PMID: 34054150 PMCID: PMC8139243 DOI: 10.1016/j.redar.2021.04.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- A Villalonga-Morales
- Servicio de Anestesiología, Reanimación y Terapéutica del Dolor, Centre Hospitalier Mère-Enfant Monkole Mont Ngafula, Kinshasa, República Democrática del Congo
| |
Collapse
|
37
|
Noori M, Shokri P, Nejadghaderi SA, Golmohammadi S, Carson-Chahhoud K, Bragazzi NL, Ansarin K, Kolahi AA, Arshi S, Safiri S. ABO blood groups and risk of human immunodeficiency virus infection: A systematic review and meta-analysis. Rev Med Virol 2021; 32:e2298. [PMID: 34590759 DOI: 10.1002/rmv.2298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2021] [Revised: 09/10/2021] [Accepted: 09/12/2021] [Indexed: 11/09/2022]
Abstract
The last few decades have seen a pandemic of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), which continues to cause substantial morbidity and mortality. ABO blood groups are anthropological and genetic characteristics of a population whose associations with HIV infection are still controversial. This systematic review with meta-analysis was undertaken to investigate whether certain blood groups may have associations with HIV infection. PubMed, Scopus and Web of Science databases were systematically searched as of 6 September 2021. Grey literature was identified through screening Google Scholar, and reference lists of relevant studies. All observational studies providing data on ABO blood group distribution among HIV-infected and uninfected participants were included. Using a random effect model, risk ratios (RR) and 95% confidence intervals (CIs) were pooled to quantify this relationship. Fifty eligible studies with a total of 3,068,244 participants and 6508 HIV-infected cases were included. The overall analysis found that blood group AB increased the risk of HIV infection by 19% as compared with non-AB blood groups (RR = 1.19, 95% CI: 1.03-1.39, p = 0.02). Pooled estimates for other blood groups failed to reach statistical significance. Subgroup analyses identified a positive relationship between AB blood group and HIV infection within Asia, patient populations (as opposed to blood donors and general populations), studies with lower sample sizes, high-income countries and studies with a moderate quality score. The sequential omission and re-analysis of studies within sensitivity analyses produced no change in the overall pooled effect. In conclusion, this study identified that blood group AB carriers were more susceptible to HIV infection. Future investigations should be directed toward clarification of the exact role of ABO blood groups in HIV infection and the possible underlying mechanisms.
Collapse
Affiliation(s)
- Maryam Noori
- Student Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Pourya Shokri
- School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Seyed Aria Nejadghaderi
- School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.,Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran
| | - Saeid Golmohammadi
- School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Kristin Carson-Chahhoud
- Australian Centre for Precision Health, University of South Australia, Adelaide, South Australia, Australia.,School of Medicine, University of Adelaide, Adelaide, South Australia, Australia
| | | | - Khalil Ansarin
- Rahat Breath and Sleep Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Ali-Asghar Kolahi
- Social Determinants of Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Shahnam Arshi
- Social Determinants of Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Saeid Safiri
- Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.,Department of Community Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
| |
Collapse
|
38
|
Domènech-Montoliu S, Puig-Barberà J, Pac-Sa MR, Vidal-Utrillas P, Latorre-Poveda M, Rio-González AD, Ferrando-Rubert S, Ferrer-Abad G, Sánchez-Urbano M, Aparisi-Esteve L, Badenes-Marques G, Cervera-Ferrer B, Clerig-Arnau U, Dols-Bernad C, Fontal-Carcel M, Gomez-Lanas L, Jovani-Sales D, León-Domingo MC, Llopico-Vilanova MD, Moros-Blasco M, Notari-Rodríguez C, Ruíz-Puig R, Valls-López S, Arnedo-Pena A. ABO Blood Groups and the Incidence of Complications in COVID-19 Patients: A Population-Based Prospective Cohort Study. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2021; 18:ijerph181910039. [PMID: 34639344 PMCID: PMC8507737 DOI: 10.3390/ijerph181910039] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 07/27/2021] [Revised: 09/06/2021] [Accepted: 09/16/2021] [Indexed: 12/16/2022]
Abstract
After a COVID-19 outbreak in the Falles festival of Borriana (Spain) during March 2020, a cohort of patients were followed until October 2020 to estimate complications post-COVID-19, considering ABO blood groups (ABO). From 536 laboratory-confirmed cases, 483 completed the study (90.1%) carried by the Public Health Center of Castelló and the Emergency and Microbiology and Clinical Analysis of Hospital de la Plana Vila-real. The study included ABO determination and telephone interviews of patients. The participants had a mean age of 37.2 ± 17.1 years, 300 females (62.1%). ABO were O (41.4%), A (45.5%), B (9.1%), and AB (3.9%). We found no difference in the incidence of COVID-19 infections. A total of 159 (32.9%) patients reported one or more post-COVID-19 complications with divergent incidences after adjustment: O (32.3%), A (32.6%), B (54.1%), and AB (27.6%); B groups had more complications post-COVID-19 when compared with O group (adjusted relative risk [aRR] 95% confidence interval [CI] 1.68, 95% CI 1.24–2.27), and symptoms of fatigue (1.79, 95% CI 1.08–2.95), myalgia (2.06, 95% CI 1.10–3.84), headache (2.61, 95% CI 1.58–4.31), and disorder of vision (4.26 95% CI 1.33–13.60). In conclusion, we observed significant differences in post-COVID-19 complications by ABO, with a higher incidence in B group. Additional research is justified to confirm our results.
Collapse
Affiliation(s)
- Salvador Domènech-Montoliu
- Emergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain; (S.D.-M.); (M.L.-P.); (M.S.-U.); (G.B.-M.); (B.C.-F.); (U.C.-A.); (L.G.-L.); (D.J.-S.); (M.D.L.-V.); (R.R.-P.); (S.V.-L.)
| | | | | | - Paula Vidal-Utrillas
- Health Centers I and II, Health Department 2, 12530 Borriana, Spain; (P.V.-U.); (A.D.R.-G.); (S.F.-R.); (G.F.-A.)
| | - Marta Latorre-Poveda
- Emergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain; (S.D.-M.); (M.L.-P.); (M.S.-U.); (G.B.-M.); (B.C.-F.); (U.C.-A.); (L.G.-L.); (D.J.-S.); (M.D.L.-V.); (R.R.-P.); (S.V.-L.)
| | - Alba Del Rio-González
- Health Centers I and II, Health Department 2, 12530 Borriana, Spain; (P.V.-U.); (A.D.R.-G.); (S.F.-R.); (G.F.-A.)
| | - Sara Ferrando-Rubert
- Health Centers I and II, Health Department 2, 12530 Borriana, Spain; (P.V.-U.); (A.D.R.-G.); (S.F.-R.); (G.F.-A.)
| | - Gema Ferrer-Abad
- Health Centers I and II, Health Department 2, 12530 Borriana, Spain; (P.V.-U.); (A.D.R.-G.); (S.F.-R.); (G.F.-A.)
| | - Manuel Sánchez-Urbano
- Emergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain; (S.D.-M.); (M.L.-P.); (M.S.-U.); (G.B.-M.); (B.C.-F.); (U.C.-A.); (L.G.-L.); (D.J.-S.); (M.D.L.-V.); (R.R.-P.); (S.V.-L.)
| | | | - Gema Badenes-Marques
- Emergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain; (S.D.-M.); (M.L.-P.); (M.S.-U.); (G.B.-M.); (B.C.-F.); (U.C.-A.); (L.G.-L.); (D.J.-S.); (M.D.L.-V.); (R.R.-P.); (S.V.-L.)
| | - Belén Cervera-Ferrer
- Emergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain; (S.D.-M.); (M.L.-P.); (M.S.-U.); (G.B.-M.); (B.C.-F.); (U.C.-A.); (L.G.-L.); (D.J.-S.); (M.D.L.-V.); (R.R.-P.); (S.V.-L.)
| | - Ursula Clerig-Arnau
- Emergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain; (S.D.-M.); (M.L.-P.); (M.S.-U.); (G.B.-M.); (B.C.-F.); (U.C.-A.); (L.G.-L.); (D.J.-S.); (M.D.L.-V.); (R.R.-P.); (S.V.-L.)
| | | | | | - Lorna Gomez-Lanas
- Emergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain; (S.D.-M.); (M.L.-P.); (M.S.-U.); (G.B.-M.); (B.C.-F.); (U.C.-A.); (L.G.-L.); (D.J.-S.); (M.D.L.-V.); (R.R.-P.); (S.V.-L.)
| | - David Jovani-Sales
- Emergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain; (S.D.-M.); (M.L.-P.); (M.S.-U.); (G.B.-M.); (B.C.-F.); (U.C.-A.); (L.G.-L.); (D.J.-S.); (M.D.L.-V.); (R.R.-P.); (S.V.-L.)
| | | | - Maria Dolores Llopico-Vilanova
- Emergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain; (S.D.-M.); (M.L.-P.); (M.S.-U.); (G.B.-M.); (B.C.-F.); (U.C.-A.); (L.G.-L.); (D.J.-S.); (M.D.L.-V.); (R.R.-P.); (S.V.-L.)
| | | | | | - Raquel Ruíz-Puig
- Emergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain; (S.D.-M.); (M.L.-P.); (M.S.-U.); (G.B.-M.); (B.C.-F.); (U.C.-A.); (L.G.-L.); (D.J.-S.); (M.D.L.-V.); (R.R.-P.); (S.V.-L.)
| | - Sonia Valls-López
- Emergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain; (S.D.-M.); (M.L.-P.); (M.S.-U.); (G.B.-M.); (B.C.-F.); (U.C.-A.); (L.G.-L.); (D.J.-S.); (M.D.L.-V.); (R.R.-P.); (S.V.-L.)
| | - Alberto Arnedo-Pena
- Public Health Center, Health Department 2, 12003 Castello de la Plana, Spain;
- Department of Health Science, Public University Navarra, 31008 Pamplona, Spain
- Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain
- Correspondence: or ; Tel.: +35-622-573979
| |
Collapse
|
39
|
Ouchida T, Takamatsu S, Maeda M, Asuka T, Morita C, Kondo J, Ueda K, Miyoshi E. Challenges in the Application of Glyco-Technology to Hepatitis B Virus Therapy and Diagnosis. Viruses 2021; 13:v13091860. [PMID: 34578441 PMCID: PMC8473023 DOI: 10.3390/v13091860] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2021] [Revised: 09/13/2021] [Accepted: 09/14/2021] [Indexed: 01/05/2023] Open
Abstract
Hepatitis B virus (HBV) is a major pathogen that causes acute/chronic hepatitis. Continuous HBV infection can lead to the development of hepatocellular carcinoma (HCC). Although several different anti-HBV treatments are available for chronic hepatitis B patients, discontinuing these medications is difficult. Patients with chronic hepatitis B at high risk for HCC therefore require close observation. However, no suitable biomarkers for detecting high-risk groups for HCC exist, except for serum HBV-DNA, but a number of HCC biomarkers are used clinically, such as alpha-fetoprotein (AFP) and protein induced by vitamin K absence-II (PIVKA-II). Glycosylation is an important post-translational protein modification involved in many human pathologic conditions. HBV surface proteins contain various oligosaccharides, and several reports have described their biological functions. Inhibition of HBV glycosylation represents a potential novel anti-HBV therapy. It is thought that glycosylation of hepatocytes/hepatoma cells is also important for HBV infection, as it prevents HBV from infecting cells other than hepatocytes, even if the cells express the HBV receptor. In this review, we summarize considerable research regarding the relationship between HBV and glycosylation as it relates to the development of novel diagnostic tests and therapies for HBV.
Collapse
Affiliation(s)
- Tsunenori Ouchida
- Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, 1-7 Yamada-oka, Suita 565-0871, Japan; (T.O.); (S.T.); (M.M.); (T.A.); (C.M.); (J.K.)
| | - Shinji Takamatsu
- Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, 1-7 Yamada-oka, Suita 565-0871, Japan; (T.O.); (S.T.); (M.M.); (T.A.); (C.M.); (J.K.)
| | - Megumi Maeda
- Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, 1-7 Yamada-oka, Suita 565-0871, Japan; (T.O.); (S.T.); (M.M.); (T.A.); (C.M.); (J.K.)
| | - Tatsuya Asuka
- Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, 1-7 Yamada-oka, Suita 565-0871, Japan; (T.O.); (S.T.); (M.M.); (T.A.); (C.M.); (J.K.)
| | - Chiharu Morita
- Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, 1-7 Yamada-oka, Suita 565-0871, Japan; (T.O.); (S.T.); (M.M.); (T.A.); (C.M.); (J.K.)
- Department of Microbiology, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita 565-0871, Japan;
| | - Jumpei Kondo
- Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, 1-7 Yamada-oka, Suita 565-0871, Japan; (T.O.); (S.T.); (M.M.); (T.A.); (C.M.); (J.K.)
| | - Keiji Ueda
- Department of Microbiology, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita 565-0871, Japan;
| | - Eiji Miyoshi
- Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, 1-7 Yamada-oka, Suita 565-0871, Japan; (T.O.); (S.T.); (M.M.); (T.A.); (C.M.); (J.K.)
- Correspondence: ; Tel./Fax: +81-6-6879-2590
| |
Collapse
|
40
|
Ayatollahi AA, Aghcheli B, Amini A, Nikbakht H, Ghassemzadehpirsala P, Behboudi E, Rajabi A, Tahamtan A. Association between blood groups and COVID-19 outcome in Iranian patients. Future Virol 2021; 16:10.2217/fvl-2021-0090. [PMID: 34589135 PMCID: PMC8462120 DOI: 10.2217/fvl-2021-0090] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2021] [Accepted: 08/27/2021] [Indexed: 02/06/2023]
Abstract
Aim: Many factors have been speculated to explain the COVID-19 complex clinical phenotype. Due to the inconsistent data published on blood groups and COVID-19, we conducted a study on Iranian patients to further assess this association. Materials & methods: This retrospective study was conducted on data collected from confirmed COVID-19 hospitalized patients during March and December 2020 in a referral hospital for COVID-19, 5 Azar Hospital, Gorgan, north of Iran. A total of 1554 confirmed COVID-19 cases were enrolled in the study with blood group (ABO and Rh), demographic, and clinical data available. Results: Of 1554 patients, 1267 and 287 cases had recovered and deceased (due to COVID-19) outcomes, respectively. Most of the cases had O+ (29.6%), the least number had AB- (0.5%), and most of the deceased cases had O+ blood types (31.4%). Logistic regression analysis revealed that groups A- and B- had higher and groups B+, AB+, O+ and O- had lower odds of death than the A+ group. Conclusion: This study indicates that blood types may be related to the clinical outcome of COVID-19. Further studies with a large cohort for multiple people are required to validate this association.
Collapse
Affiliation(s)
- Ali Asghar Ayatollahi
- Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, 4934174513, Iran
| | - Bahman Aghcheli
- Department of Microbiology, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, 4934174515, Iran
| | - Abolfazl Amini
- Department of Medical Biotechnology, Faculty of Advanced Technologies in Medicine, Golestan University of Medical Sciences, Gorgan, 4934174516, Iran
| | - Hasan Nikbakht
- Faculty of Medical, Golestan University of Medical Sciences, Gorgan, 4934174515, Iran
| | | | - Emad Behboudi
- Department of Microbiology, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, 4934174515, Iran
| | - Abdolhalim Rajabi
- Biostatistics & Epidemiology Department, Faculty of Health, Environmental Health Research Center, Golestan University of Medical Sciences, Gorgan, 4934174518, Iran
| | - Alireza Tahamtan
- Department of Microbiology, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, 4934174515, Iran
- Infectious Diseases Research Center, Golestan University of Medical Sciences, Gorgan, 4934174510, Iran
| |
Collapse
|
41
|
El-Rashidy N, Abdelrazik S, Abuhmed T, Amer E, Ali F, Hu JW, El-Sappagh S. Comprehensive Survey of Using Machine Learning in the COVID-19 Pandemic. Diagnostics (Basel) 2021; 11:1155. [PMID: 34202587 PMCID: PMC8303306 DOI: 10.3390/diagnostics11071155] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2021] [Revised: 05/29/2021] [Accepted: 05/31/2021] [Indexed: 12/11/2022] Open
Abstract
Since December 2019, the global health population has faced the rapid spreading of coronavirus disease (COVID-19). With the incremental acceleration of the number of infected cases, the World Health Organization (WHO) has reported COVID-19 as an epidemic that puts a heavy burden on healthcare sectors in almost every country. The potential of artificial intelligence (AI) in this context is difficult to ignore. AI companies have been racing to develop innovative tools that contribute to arm the world against this pandemic and minimize the disruption that it may cause. The main objective of this study is to survey the decisive role of AI as a technology used to fight against the COVID-19 pandemic. Five significant applications of AI for COVID-19 were found, including (1) COVID-19 diagnosis using various data types (e.g., images, sound, and text); (2) estimation of the possible future spread of the disease based on the current confirmed cases; (3) association between COVID-19 infection and patient characteristics; (4) vaccine development and drug interaction; and (5) development of supporting applications. This study also introduces a comparison between current COVID-19 datasets. Based on the limitations of the current literature, this review highlights the open research challenges that could inspire the future application of AI in COVID-19.
Collapse
Affiliation(s)
- Nora El-Rashidy
- Machine Learning and Information Retrieval Department, Faculty of Artificial Intelligence, Kafrelsheiksh University, Kafrelsheiksh 13518, Egypt
| | - Samir Abdelrazik
- Information System Department, Faculty of Computer Science and Information Systems, Mansoura University, Mansoura 13518, Egypt;
| | - Tamer Abuhmed
- College of Computing and Informatics, Sungkyunkwan University, Seoul 03063, Korea
| | - Eslam Amer
- Faculty of Computer Science, Misr International University, Cairo 11828, Egypt;
| | - Farman Ali
- Department of Software, Sejong University, Seoul 05006, Korea;
| | - Jong-Wan Hu
- Department of Civil and Environmental Engineering, Incheon National University, Incheon 22012, Korea
| | - Shaker El-Sappagh
- Centro Singular de Investigación en Tecnoloxías Intelixentes (CiTIUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
- Information Systems Department, Faculty of Computers and Artificial Intelligence, Benha University, Banha 13518, Egypt
| |
Collapse
|